

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2015/066612 A2

(43) International Publication Date

7 May 2015 (07.05.2015)

(51) International Patent Classification:

C07F 5/02 (2006.01)

(21) International Application Number:

PCT/US2014/063692

(22) International Filing Date:

3 November 2014 (03.11.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/899,296 3 November 2013 (03.11.2013) US

(71) Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS [US/US]; 352 Henry Administration Building, 506 S. Wright Street, Urbana, IL 61801 (US).

(72) Inventors: BURKE, Martin, D.; 1403 Old Farm Road, Champaign, IL 61821 (US). WANG, Pulin; 6506 Hillside Hollow Drive, Austin, TX 78750 (US). CROUCH, Ian; 1024 E. Kerr Ave. #301, Urbana, IL 61802 (US).

(74) Agents: STEELE, Alan, W. et al.; Foley Hoag LLP, Seaport West, 155 Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))



WO 2015/066612 A2

(54) Title: CROSS-CO尤LING OF UNACTIVATED SECONDARY BORONIC ACIDS

(57) Abstract: Provided are methods for site- and stereo-retentive cross-couplings with unactivated secondary boronic acids, particularly useful in building block-based approach for small molecule synthesis. Also provided is a method of forming an air-stable chiral secondary boronic acid.

CROSS-COUPLING OF UNACTIVATED SECONDARY BORONIC ACIDS**RELATED APPLICATION**

This application claims benefit of U.S. Provisional Patent Application No. 61/899,296, filed November 3, 2013.

5

**STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR
DEVELOPMENT**

This invention was made with government support under contract number GM080436 awarded by the National Institutes of Health. The government has certain rights 10 in the invention.

BACKGROUND OF THE INVENTION

The Suzuki-Miyaura reaction is a palladium- or nickel-catalyzed cross coupling between a boronic acid or a boronic ester and an organohalide or an organo-pseudohalide.

15 Miyaura, A. *Chem. Rev.*, 1995. This cross coupling transformation is a powerful method for C—C bond formation in complex molecule synthesis. The reaction is tolerant of functional groups and has become increasingly general and widespread in its use for coupling of organic compounds. Barder, T. E. et al., *J. Am. Chem. Soc.* 2005, 127, 4685-4696; Billingsley, K. et al., *J. Am. Chem. Soc.* 2007, 129, 3358-3366; Little, A. F. et al., *J. Am. Chem. Soc.* 2000, 122, 4020-4028; Nicolaou, K. C. et al., *Angew. Chem. Int. Ed.* 2005, 44, 20 4442-4489.

Boronic acids are notoriously sensitive to many common reagents. Hall, D. G., *Boronic Acids*, Wiley-VCH, Germany, 2005, pp. 3-14; Tyrell, E. et al., *Synthesis* 2003, 4, 25 469-483. It is therefore typical to introduce the boronic acid functional group during the last step of a building block synthesis. However, many of the methods for doing so (hydroboration, trapping organometallic reagents with trimethylborate, etc.) are intolerant to a variety of common functional groups, such as alcohols, aldehydes, ketones, alkynes and olefins. This makes the synthesis of structurally complex boronic acid building blocks quite challenging.

30 Peptides, oligonucleotides, and increasingly oligosaccharides can be rapidly and flexibly prepared in the laboratory from readily accessible building blocks having all of the required site- and stereochemical information pre-installed.¹ The inherent modularity of many small molecules and the rapidly expanding scope of boronic acid cross-coupling

chemistry²⁻⁴ collectively support the notion that an analogous building block-based approach for small molecule synthesis may be attainable.⁵ However, at present, unactivated Csp³ organoboronates cannot be cross-coupled with the same levels of efficiency, site-, and stereo-retention that is now accessible with many of their Csp² and activated Csp³

5 hybridized counterparts.²⁻⁴ Solving this problem stands to enable a wide range of stereochemically complex natural products and Csp³-rich pharmaceuticals⁷ to be more efficiently and flexibly prepared via the simple site- and stereo-retentive assembly of off-

US 8,013,203 (incorporated by reference), US 8,318,983 (incorporated by reference), and US 2013/0296573 (incorporated by reference), each to Burke et al., disclose 10 protected organoboronic acid compounds comprising a boron having an sp³ hybridization, a conformationally rigid protecting group bonded to the boron, and an organic group bonded to the boron through a boron-carbon bond; methods of making same; and methods of performing chemical reactions using same. In an embodiment, the protected organoboronic acid is an N-methyliminodiacetic acid (MIDA) boronate.

15 US 8,338,601 (incorporated by reference) and US 2013/0317223 (incorporated by reference), each to Burke et al., disclose methods of performing chemical reactions using protected organoboronic acid compounds. In an embodiment, the protected organoboronic acid is a MIDA boronate. In an embodiment, the reaction is a cross-coupling reaction.

20 US 8,557,980 (incorporated by reference) and US 2014/0073785 (incorporated by reference), each to Burke et al., disclose methods of forming protected boronic acids that provide a wide variety of building blocks for use in chemical reactions. In an embodiment, the protected boronic acid is a MIDA boronate. In an embodiment, the reaction is a cross-coupling reaction.

25 US 2013/0243670 (incorporated by reference) to Burke et al. discloses methods and an apparatus for purification of MIDA boronates and deprotection of boronic acids from their MIDA ligands to perform cross-coupling reactions. Iterative cycles of deprotection, coupling, and purification can be used to synthesize small molecules.


30 US 2014/0094615 (incorporated by reference) to Burke et al. discloses methods of making and using chiral, non-racemic protected organoboronic acid compounds to direct and enable stereoselective synthesis of organic molecules. In an embodiment, the chiral, non-racemic protected organoboronic acid compounds are chiral derivatives of iminodiacetic acid (IDA).

SUMMARY OF THE INVENTION

One aspect of the invention is a method for site- and stereo-retentive cross-couplings of an aryl halide with an unactivated secondary boronic acid. The method is characterized by mild reaction conditions, operationally simplicity, and the use of an air-stable and commercially available catalyst. The method can employ chiral non-racemic boronic acids, which are readily prepared via resolution with a non-racemic chiral substituted iminodiacetic acid (IDA). Taken together the steps of resolution and cross-coupling represent an important step towards adding stereogenic secondary carbon-containing fragments to the growing list of substructures compatible with a general, building block-based approach to the synthesis of small molecules.

An aspect of the invention is a method of forming a product represented by R^1R^2CH-Ar , comprising:

15 combining a secondary boronic acid represented by $R^1R^2CH-B(OH)_2$; an aryl halide represented by $Ar-X$; a Pd catalyst; a ligand; and Ag_2O :



wherein, independently for each occurrence,

20 R^1 and R^2 are selected from the group consisting of substituted C_1-C_6 alkyl and unsubstituted C_1-C_6 alkyl; or R^1 and R^2 , taken together with the carbon to which they are joined, form a substituted or unsubstituted C_3-C_8 cycloalkyl;

Ar represents a substituted or unsubstituted monocyclic or polycyclic aryl;

X represents halogen;

Pd catalyst represents Pd(0) or Pd(II);

ligand is $P(o-R\text{-phenyl})_3$; and

25 R represents C_1-C_4 alkyl;

thereby forming a product represented by R^1R^2CH-Ar .

In certain embodiments, the secondary boronic acid is achiral.

In certain embodiments, the secondary boronic acid is chiral.

In certain embodiments, the secondary boronic acid is a racemic mixture.

30 In certain embodiments, the secondary boronic acid is not a racemic mixture.


In certain embodiments, the secondary boronic acid has an enantiomeric excess of at least 80 percent. In certain embodiments, the secondary boronic acid has an enantiomeric excess of at least 90 percent. In certain embodiments, the secondary boronic acid has an enantiomeric excess of at least 95 percent.

5 In certain embodiments, the product represented by R^1R^2CH-Ar is not a racemic mixture.

In certain embodiments, the product represented by R^1R^2CH-Ar has an enantiomeric excess of at least 80 percent. In certain embodiments, the product represented by R^1R^2CH-Ar has an enantiomeric excess of at least 90 percent. In certain embodiments, the product represented by R^1R^2CH-Ar has an enantiomeric excess of at least 95 percent.

An aspect of the invention is a method of forming an air-stable chiral secondary boronic acid, wherein the air-stable chiral secondary boronic acid is not a racemic mixture, comprising:

combining a chiral secondary boronic acid represented by formula (I)



(I)

wherein, independently for each occurrence, R^1 and R^2 are selected from the group consisting of substituted C_1-C_6 alkyl and unsubstituted C_1-C_6 alkyl; a chiral iminodiacetic acid, wherein the chiral iminodiacetic acid is not a racemic mixture; a weak acid catalyst; and a polar aprotic solvent, thereby forming a mixture of chiral boronates;

20 resolving the mixture of chiral boronates into individual diastereomers; and hydrolyzing an individual diastereomer, thereby forming an air-stable chiral secondary boronic acid, wherein the air-stable chiral secondary boronic acid is not a racemic mixture.

25 In certain embodiments, the chiral iminodiacetic acid has an enantiomeric excess of at least 80 percent. In certain embodiments, the chiral iminodiacetic acid has an enantiomeric excess of at least 90 percent. In certain embodiments, the chiral iminodiacetic acid has an enantiomeric excess of at least 95 percent.

30 In certain embodiments, the chiral iminodiacetic acid is benzylcyclopentyl iminodiacetic acid (BIDA).


In certain embodiments, the chiral secondary boronic acid represented by formula (I) is a racemic mixture.

In certain embodiments, the chiral secondary boronic acid represented by formula (I) is not a racemic mixture.


5 In certain embodiments, the air-stable chiral secondary boronic acid has an enantiomeric excess of at least 80 percent. In certain embodiments, the air-stable chiral secondary boronic acid has an enantiomeric excess of at least 90 percent. In certain embodiments, the air-stable chiral secondary boronic acid has an enantiomeric excess of at least 95 percent.

10 An aspect of the invention is a method of forming an air-stable trihydroxyborate salt of a primary or secondary boronic acid, comprising:

(i) combining a primary or secondary boronate represented by formula (II):



15 a first polar aprotic solvent, and aqueous hydroxide, thereby forming a primary or secondary boronic acid represented by formula (I):



wherein, independently for each occurrence,

20 R^1 is selected from the group consisting of substituted $\text{C}_1\text{-}\text{C}_6$ alkyl and unsubstituted $\text{C}_1\text{-}\text{C}_6$ alkyl;

R^2 is selected from the group consisting of H, substituted $\text{C}_1\text{-}\text{C}_6$ alkyl and unsubstituted $\text{C}_1\text{-}\text{C}_6$ alkyl; and

25 R^a and R^b are selected from the group consisting of optionally substituted alkyl, aryl, and acyl; or R^a and R^b taken together with the $-\text{O}-\text{B}(\text{CHR}^1\text{R}^2)-\text{O}-$ moiety to which they are attached form an optionally substituted heterocyclic ring consisting of 5-10 heavy atoms in the backbone of said heterocyclic ring, wherein 3-5 heteroatoms selected independently from the group consisting of B, O, and N are present in said heterocyclic ring; and

(ii) combining the primary or secondary boronic acid represented by formula (I), an ether, and concentrated hydroxide, thereby forming an air-stable trihydroxyborate salt of a primary or secondary boronic acid.

5 In certain embodiments, the method further comprises combining the air-stable trihydroxyborate salt of a primary or secondary boronic acid, a Lewis acid, and a second polar aprotic solvent, thereby re-forming the primary or secondary boronic acid represented by formula (I).

In certain embodiments, the primary or secondary boronate represented by formula (II) is achiral.

10 In certain embodiments, the primary or secondary boronic acid represented by formula (I) is a primary boronic acid.

In certain embodiments, the primary or secondary boronic acid represented by formula (I) is a secondary boronic acid.

15 In certain embodiments, the primary or secondary boronate represented by formula (II) is chiral.

In certain embodiments, the chiral primary or secondary boronate represented by formula (II) is a racemic mixture.

In certain embodiments, the chiral primary or secondary boronate represented by formula (II) is not a racemic mixture.


20 In certain embodiments, the air-stable salt of the primary or secondary boronic acid is a chiral air-stable salt of the secondary boronic acid.

In certain embodiments, the chiral air-stable salt of the secondary boronic acid is a racemic mixture.

25 In certain embodiments, the chiral air-stable salt of the secondary boronic acid is not a racemic mixture.

In certain embodiments, the chiral air-stable salt of the secondary boronic acid has an enantiomeric excess of at least 80 percent.

An aspect of the invention is a method of forming a boronic acid, comprising the steps represented by:



wherein

R^a represents an organic group; and

MIDA represents N-methyliminodiacetic acid.

In certain embodiments, the organic group is a chiral organic group; and the boronic

5 acid R^a  is a chiral boronic acid.

In certain embodiments, the chiral organic group is a racemic mixture; and the chiral boronic acid is a racemic mixture.

In certain embodiments, the chiral organic group is not a racemic mixture; and the chiral boronic acid is not a racemic mixture.

10 In certain embodiments, the chiral organic group has an enantiomeric excess of at least 80 percent. In certain embodiments, the chiral organic group has an enantiomeric excess of at least 90 percent. In certain embodiments, the chiral organic group has an enantiomeric excess of at least 95 percent.

15 In certain embodiments, the chiral boronic acid has an enantiomeric excess of at least 80 percent. In certain embodiments, the chiral boronic acid has an enantiomeric excess of at least 90 percent. In certain embodiments, the chiral boronic acid has an enantiomeric excess of at least 95 percent.

BRIEF DESCRIPTION OF THE DRAWINGS

20 **Figure 1** depicts a scheme for preparing desired and undesired products of cross-coupling of unactivated chiral secondary boronic acids (Scheme 1).

Figure 2 depicts a scheme for stabilization of an unstable secondary boronic acid and deprotection of the stabilized secondary boronic acid (Scheme 2).

25 **Figure 3** depicts a scheme for cross-coupling a chiral non-racemic secondary boronic acid with high site- and stereo-retention (Scheme 3).

30 **Figure 4** depicts an exemplary series of steps for preparing a chiral nonracemic boronic acid from a diastereomerically enriched cyclic boronate via the intermediacy of a stable chiral nonracemic sodium trihydroxyborate salt. The series of steps can be applied to any of a range of cyclic boronates to produce boronic acids from cyclic boronates via the intermediacy of stable sodium trihydroxyborate salts.

DETAILED DESCRIPTION

Definitions

Unless otherwise explained, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which a 5 disclosed disclosure belongs.

For the purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 67th Ed., 1986-1987, inside cover.

The term “acyl” or “acyl group” means any group or radical of the form –C(=O)R, 10 where R is an organic group. An example of the acyl group is the acetyl group (-C(=O)CH₃).

The term “acyloxy” or “acyloxy group” as used herein refers to means an acyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.

The term “alkenyl” or “alkenyl group” means a group formed by removing a 15 hydrogen from a carbon of an alkene, where an alkene is an acyclic or cyclic compound consisting entirely of hydrogen atoms and carbon atoms, and including at least one carbon-carbon double bond. An alkenyl group may include one or more substituent groups.

The term “alkoxy” or “alkoxy group” as used herein means an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.

20 Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy. The terms “alkylenyloxy”, “alkynyloxy”, “carbocyclxyloxy”, and “heterocyclxyloxy” are likewise defined.

The term “alkyl” or “alkyl group” means a group formed by removing a hydrogen 25 from a carbon of an alkane, where an alkane is an acyclic or cyclic compound consisting entirely of hydrogen atoms and saturated carbon atoms. In various embodiments an alkyl contains 1 to 20, 1 to 15, or 1 to 10 carbon atoms. In one embodiment an alkyl contains 1 to 3 carbon atoms. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 2-methylcyclopentyl, 1-(1-ethylcyclopropyl)ethyl and 1-cyclohexylethyl. An alkyl group may include one or more substituent groups.

The term “alkynyl group” means a group formed by removing a hydrogen from a carbon of an alkyne, where an alkyne is an acyclic or cyclic compound consisting entirely

of hydrogen atoms and carbon atoms, and including at least one carbon-carbon triple bond. An alkynyl group may include one or more substituent groups.

The term “amino”, “amino group”, or “amine” as used herein refers to -NH₂ and substituted derivatives thereof wherein one or both of the hydrogens are independently replaced with substituents selected from the group consisting of alkyl, haloalkyl, fluoroalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkylcarbonyl, haloalkylcarbonyl, fluoroalkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, carbocyclylcarbonyl, heterocyclylcarbonyl, arylcarbonyl, aralkylcarbonyl, heteroarylcarbonyl, heteroaralkylcarbonyl, sulfonyl, and sulfinyl groups; or when both hydrogens together are replaced with an alkylene group (to form a ring which contains the nitrogen). Representative examples include, but are not limited to methylamino, acetylamino, and dimethylamino.

The term “amido” as used herein means an amino group, as defined herein, appended to the parent molecular moiety through a carbonyl.

The term “arylalkyl” or “aralkyl” as used herein means an aryl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of aralkyl include, but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl, and 2-naphth-2-ylethyl.

The term “aromatic” or “aromatic group” refers to a planar or polycyclic structure characterized by a cyclically conjugated molecular moiety containing 4n+2 electrons, wherein n is the absolute value of an integer. Aromatic molecules containing fused, or joined, rings also are referred to as bicyclic aromatic rings. For example, bicyclic aromatic rings containing heteroatoms in a hydrocarbon ring structure are referred to as bicyclic heteroaryl rings.

The term “aryl” or “aryl group” means a group formed by removing a hydrogen from a ring carbon atom of an aromatic hydrocarbon. An aryl group may be monocyclic or polycyclic and may include one or more substituent groups.

The term “aryloxy” or “aryloxy group” as used herein means an aryl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. The term “heteroaryloxy” or “heteroaryloxy group” as used herein means a heteroaryl group, as defined herein, appended to the parent molecular moiety through an oxygen atom. An aryloxy group may include one or more substituent groups.

The term “azido” as used herein means a -N₃ group.

The term “carbonyl” as used herein refers to a $-\text{C}(=\text{O})-$ group.

The term “chemical transform” of a substance means a product of a chemical transformation of the substance, where the product has a chemical structure different from that of the substance.

5 The term “chemical transformation” means the conversion of a substance into a product, irrespective of reagents or mechanisms involved.

The term “cyano” as used herein means a $-\text{C}\equiv\text{N}$ group.

The term “cyclic” pertains to compounds and/or groups which have one or more rings (e.g., spiro, fused, bridged).

10 The term “cycloalkyl” or “cycloalkyl group” is a subset of alkyl which refers to a cyclic hydrocarbon radical containing from 3 to 15, 3 to 10, or 3 to 7 carbon atoms.

Representative examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. A cycloalkyl group may include one or more substituent groups.

15 The term “enantiomeric excess” (ee) means the absolute difference between the mole fraction of each enantiomer.

The term “functional group” means an atom or collection of atoms in a molecule that are responsible for characteristic chemical reactions of the molecule. Nonlimiting examples of functional groups include halogen, alcohol ($-\text{OH}$), aldehyde ($-\text{CH}=\text{O}$), ketone ($-\text{C}(=\text{O})-$), carboxylic acid ($-\text{C}(=\text{O})\text{OH}$), thiol ($-\text{SH}$), sulfone, sulfoxide, amine, phosphine, phosphite, phosphate, and combinations thereof. Of particular interest as functional groups in connection with the invention are alkenyl (olefinic) groups. Additional examples of organic groups including functional groups that may be present in a protected organoboronic acid are illustrated or described throughout the present application.

25 The term “group” means a linked collection of atoms or a single atom within a molecular entity, where a molecular entity is any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer, etc., identifiable as a separately distinguishable entity. The description of a group as being “formed by” a particular chemical transformation does not imply that this chemical transformation is involved in making the molecular entity that includes the group.

30 The term “halogen” means $-\text{F}$, $-\text{Cl}$, $-\text{Br}$ or $-\text{I}$.

The term “heteroalkenyl” or “heteroalkenyl group” means a group formed by removing a hydrogen from a carbon of a heteroalkene, where a heteroalkene is an acyclic or

cyclic compound consisting entirely of hydrogen atoms, carbon atoms, and one or more heteroatoms, and including at least one carbon-carbon double bond. A heteroalkenyl group may include one or more substituent groups.

The term “heteroalkyl group” means a group formed by removing a hydrogen from a carbon of a heteroalkane, where a heteroalkane is an acyclic or cyclic compound consisting entirely of hydrogen atoms, saturated carbon atoms, and one or more heteroatoms. A heteroalkyl group may include one or more substituent groups.

The term “heteroalkynyl” or “heteralkynyl group” means a group formed by removing a hydrogen from a carbon of a heteroalkyne, where a heteroalkyne is an acyclic or cyclic compound consisting entirely of hydrogen atoms, carbon atoms and one or more heteroatoms, and including at least one carbon-carbon triple bond. A heteroalkynyl group may include one or more substituent groups.

The term “heteroaralkyl”, “heteroaralkyl group”, “heteroarylalkyl”, or “heteroarylalkyl group” as used herein means a heteroaryl, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein. Representative examples of heteroarylalkyl include, but are not limited to, pyridin-3-ylmethyl and 2-(thien-2-yl)ethyl. A heteroaralkyl group may include one or more substituent groups.

The term “heteroaromatic” or “heteroaromatic group” as used herein means an aromatic group as defined herein, in which at least one carbon atom is replaced by a heteroatom. Representative examples of heteroaromatic groups include, without limitation, pyrrolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, pyridinyl, pyrimidinyl, purinyl, quinolinyl, isoquinolinyl, and carbazolyl. A heteroaromatic group may include one or more substituent groups.

The term “heteroaryl” or “heteroaryl group” as used herein means a radical of aromatic ring systems, including, but not limited to, monocyclic, bicyclic and tricyclic rings, which have 3 to 12 atoms including at least one heteroatom, such as nitrogen, oxygen, or sulfur. Representative examples of heteroaryl groups include, without limitation, aminobenzimidazolyl, benzimidazolyl, azaindolyl, benzo(b)thienyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl, benzoxadiazolyl, furanyl, imidazolyl, imidazopyridinyl, indolyl, indolinyl, indazolyl, isoindolinyl, isoxazolyl, isothiazolyl, isoquinolinyl, oxadiazolyl, oxazolyl, purinyl, pyranyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-d]pyrimidinyl, quinolinyl, quinazolinyl, triazolyl, thiazolyl,

thiophenyl, tetrahydroindolyl, tetrazolyl, thiadiazolyl, thienyl, thiomorpholinyl, triazolyl or tropanyl. The heteroaryl groups of the invention may include one or more substituent groups.

5 The term “heteroatom” means any atom that is not carbon or hydrogen. In certain embodiments a heteroatom is an atom selected from any of nitrogen, oxygen, sulfur, and phosphorus.

10 The term “heterocyclyl”, “heterocyclic”, or “heterocyclic group” as used herein refers to a radical of a non-aromatic ring system, including, but not limited to, monocyclic, bicyclic and tricyclic rings, which can be completely saturated or which can contain one or more units of unsaturation, and has 3 to 12 atoms including at least one heteroatom, such as 15 nitrogen, oxygen, or sulfur. For the avoidance of doubt, the degree of unsaturation does not result in an aromatic ring system. For purposes of exemplification, which should not be construed as limiting the scope of this invention, the following are examples of heterocyclic rings: aziridinyl, azirinyl, oxiranyl, thiiranyl, thiirenyl, dioxiranyl, diazirinyl, azetyl, oxetanyl, oxetyl, thietanyl, thietyl, diazetidinyl, dioxtetanyl, dioxetanyl, dithietanyl, 20 dithietyl, furyl, dioxalanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, triazolyl, triazinyl, isothiazolyl, isoxazolyl, thiophenyl, pyrazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, tetrazinyl, quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, pyridopyrazinyl, benzoxazolyl, benzothiophenyl, 25 benzimidazolyl, benzothiazolyl, benzoxadiazolyl, benzthiadiazolyl, indolyl, benztriazolyl, naphthyridinyl, azepines, azetidinyl, morpholinyl, oxopiperidinyl, oxopyrrolidinyl, piperazinyl, piperidinyl, pyrrolidinyl, quinclidinyl, thiomorpholinyl, tetrahydropyranyl and tetrahydrofuranyl. The heterocyclyl groups of the invention may include one or more substituent groups.

25 The term “heteroaryl group” means a group formed by replacing one or more methine (–C=) and/or vinylene (–CH=CH–) groups in an aryl group with a trivalent or divalent heteroatom, respectively. A heteroaryl group may be monocyclic or polycyclic and may include one or more substituent groups.

The term “hydroxyl” or “hydroxyl group” as used herein means an -OH group.

30 The term “organic group” means a group containing at least one carbon atom.

The term “organoboronic acid” means a compound represented by R – B(OH)₂, where R is an organic group that is bonded to the boron through a boron-carbon bond.

The term “phosphinyl” as used herein includes -PH₃ and substituted derivatives thereof wherein one, two or three of the hydrogens are independently replaced with substituents selected from the group consisting of alkyl, haloalkyl, fluoroalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkoxy, 5 haloalkoxy, fluoroalkyloxy, alkenyloxy, alkynyoxy, carbocyclyoxy, heterocyclyoxy, aryloxy, aralkyloxy, heteroaryloxy, heteroaralkyloxy, and amino.

The term “phosphoryl” as used herein refers to -P(=O)OH₂ and substituted derivatives thereof wherein one or both of the hydroxyls are independently replaced with substituents selected from the group consisting of alkyl, haloalkyl, fluoroalkyl, alkenyl, 10 alkynyl, carbocyclyl, heterocyclyl, aryl, aralkyl, heteroaryl, heteroaralkyl, alkoxy, haloalkoxy, fluoroalkyloxy, alkenyloxy, alkynyoxy, carbocyclyoxy, heterocyclyoxy, aryloxy, aralkyloxy, heteroaryloxy, heteroaralkyloxy, and amino.

As used herein, a “polar aprotic solvent” is a solvent that will dissolve many salts, but lacks an acidic hydrogen; these solvents generally have intermediate to high dielectric 15 constants and polarity. Non-limiting examples of polar aprotic solvents include acetone, acetonitrile, dichloromethane (DCM), dimethyl sulfoxide (DMSO), ethyl acetate, hexamethylphosphoric triamide (HMPT), *N,N*-dimethylformamide (DMF), and tetrahydrofuran (THF).

The term “protected organoboronic acid” means a chemical transform of an 20 organoboronic acid, in which the boron has a lower chemical reactivity relative to the original organoboronic acid.

The term “silyl” as used herein includes H₃Si- and substituted derivatives thereof wherein one, two or three of the hydrogens are independently replaced with substituents selected from alkyl, haloalkyl, fluoroalkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl, 25 aralkyl, heteroaryl, and heteroaralkyl. Representative examples include trimethylsilyl (TMS), tert-butyldiphenylsilyl (TBDPS), tert-butyldimethylsilyl (TBS/TBDMS), triisopropylsilyl (TIPS), and [2-(trimethylsilyl)ethoxy]methyl (SEM).

The term “sp³ hybridization” means that an atom is bonded and/or coordinated in a configuration having a tetrahedral character of at least 50%. For tetra-coordinate boron 30 atoms, the tetrahedral character of the boron atom is calculated by the method of Höpfl, H. (1999) *J Organomet Chem* 581:129-49. In this method, the tetrahedral character (THC) is defined as:

$$\text{THC}_{\text{DA}}(\%) = 100 \times (1 - (\sum_{n=1-6} |109.5 - \theta_n|^\circ / 90^\circ))$$

where θ_n is one of the six bond angles of the boron atom.

The term “substituent” or “substituent group” means a group that replaces one or more hydrogen atoms in a molecular entity. Except as may be specified otherwise, substituent groups can include, without limitation, alkyl, alkenyl, alkynyl, halo, haloalkyl, 5 fluoroalkyl, hydroxy, alkoxy, alkyenyl, alkynyl, carbocyclxy, heterocyclxy, haloalkoxy, fluoroalkyloxy, sulfhydryl, alkylthio, haloalkylthio, fluoroalkylthio, alkyenylthio, alkynylthio, sulfonic acid, alkylsulfonyl, haloalkylsulfonyl, fluoroalkylsulfonyl, alkenylsulfonyl, alkynylsulfonyl, alkoxyssulfonyl, haloalkoxysulfonyl, fluoroalkoxysulfonyl, alkenyloxysulfonyl, alkynyloxysulfonyl, aminosulfonyl, sulfinic acid, 10 alkylsulfinyl, haloalkylsulfinyl, fluoroalkylsulfinyl, alkenylsulfinyl, alkynylsulfinyl, alkoxyssulfinyl, haloalkoxysulfinyl, fluoroalkoxysulfinyl, alkenyloxysulfinyl, alkynyloxysulfinyl, alkynyloxysulfiny, aminosulfinyl, formyl, alkylcarbonyl, haloalkylcarbonyl, fluoroalkylcarbonyl, alkenylcarbonyl, alkynylcarbonyl, carboxyl, alkoxy carbonyl, haloalkoxycarbonyl, fluoroalkoxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, 15 alkylcarbonyloxy, haloalkylcarbonyloxy, fluoroalkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkylsulfonyloxy, haloalkylsulfonyloxy, fluoroalkylsulfonyloxy, alkenylsulfonyloxy, alkynylsulfonyloxy, haloalkoxysulfonyloxy, fluoroalkoxysulfonyloxy, alkenyloxysulfonyloxy, alkynyloxysulfonyloxy, alkylsulfinyloxy, haloalkylsulfinyloxy, fluoroalkylsulfinyloxy, alkenylsulfinyloxy, alkynylsulfinyloxy, alkoxy sulfinyloxy, 20 haloalkoxysulfinyloxy, fluoroalkoxysulfinyloxy, alkenyloxysulfinyloxy, alkynyloxysulfinyloxy, aminosulfinyloxy, amino, amido, aminosulfonyl, aminosulfinyl, cyano, nitro, azido, phosphinyl, phosphoryl, silyl, and silyloxy.

The term “sulfinyl” as used herein refers to a $-S(=O)-$ group.

The term “sulfonyl” as used herein refers to a $-S(=O)_2-$ group.

The term “trialkylsilyloxy” or “trialkylsilyloxy group” as used herein refers to a trialkylsilyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.

The articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

The phrase “and/or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple

elements listed with “and/or” should be construed in the same fashion, i.e., “one or more” of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the “and/or” clause, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, a reference to “A and/or 5 B”, when used in conjunction with open-ended language such as “comprising” can refer, in one embodiment, to A only (optionally including elements other than B); in another embodiment, to B only (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements); etc.

As used herein in the specification and in the claims, “or” should be understood to 10 have the same meaning as “and/or” as defined above. For example, when separating items in a list, “or” or “and/or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as “only one of” or “exactly one of,” or, when used in the claims, “consisting of,” will refer to the 15 inclusion of exactly one element of a number or list of elements. In general, the term “or” as used herein shall only be interpreted as indicating exclusive alternatives (i.e., “one or the other but not both”) when preceded by terms of exclusivity, such as “either,” “one of,” “only one of,” or “exactly one of.” “Consisting essentially of,” when used in the claims, shall have its ordinary meaning as used in the field of patent law.

As used herein in the specification and in the claims, the phrase “at least one,” in 20 reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements.

This definition also allows that elements may optionally be present other than the elements 25 specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified. Thus, as a non-limiting example, “at least one of A and B” (or, equivalently, “at least one of A or B,” or, equivalently “at least one of A and/or B”) can refer, in one embodiment, to at least one, 30 optionally including more than one, A, with no B present (and optionally including elements other than B); in another embodiment, to at least one, optionally including more than one, B, with no A present (and optionally including elements other than A); in yet

another embodiment, to at least one, optionally including more than one, A, and at least one, optionally including more than one, B (and optionally including other elements); etc.

As used herein, “comprising” is synonymous with “including,” “containing,” or “characterized by,” and is inclusive or open-ended and does not exclude additional, 5 unrecited elements or method steps. As used herein, “consisting of” excludes any element, step, or ingredient not specified in the claim element. As used herein, “consisting essentially of” does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim. In each instance herein any of the terms “comprising”, “consisting essentially of” and “consisting of” may be replaced with either of the other two 10 terms. The disclosure illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein.

In the claims, as well as in the specification herein, all transitional phrases such as “comprising,” “including,” “carrying,” “having,” “containing,” “involving,” “holding,” 15 “composed of,” and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases “consisting of” and “consisting essentially of” shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.

It should also be understood that, unless clearly indicated to the contrary, in any 20 methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.

When a group of substituents is disclosed herein, it is understood that all individual 25 members of that group and all subgroups, including any isomers, enantiomers, and diastereomers of the group members, are disclosed separately. When a Markush group or other grouping is used herein, all individual members of the group and all combinations and subcombinations possible of the group are intended to be individually included in the disclosure. When a compound is described herein such that a particular isomer, enantiomer or diastereomer of the compound is not specified, for example, in a formula or in a 30 chemical name, that description is intended to include each isomers and enantiomer of the compound described individual or in any combination. Additionally, unless otherwise specified, all isotopic variants of compounds disclosed herein are intended to be encompassed by the disclosure. For example, it will be understood that any one or more

hydrogens in a molecule disclosed can be replaced with deuterium or tritium. Isotopic variants of a molecule are generally useful as standards in assays for the molecule and in chemical and biological research related to the molecule or its use. Methods for making such isotopic variants are known in the art. Specific names of compounds are intended to be 5 exemplary, as it is known that one of ordinary skill in the art can name the same compounds differently.


Many of the molecules disclosed herein contain one or more ionizable groups, i.e., groups from which a proton can be removed (e.g., -COOH) or added (e.g., amines) or which can be quaternized (e.g., amines). All possible ionic forms of such molecules and 10 salts thereof are intended to be included individually in the disclosure herein. With regard to salts of the compounds herein, one of ordinary skill in the art can select from among a wide variety of available counterions those that are appropriate for preparation of salts of this disclosure for a given application. In specific applications, the selection of a given anion or cation for preparation of a salt may result in increased or decreased solubility of 15 that salt.

Every formulation or combination of components described or exemplified herein can be used to practice the disclosure, unless otherwise stated.

Whenever a range is given in the specification, for example, a temperature range, a time range, or a composition or concentration range, all intermediate ranges and subranges, 20 as well as all individual values included in the ranges given are intended to be included in the disclosure. It will be understood that any subranges or individual values in a range or subrange that are included in the description herein can be excluded from the claims herein.

Protected Organoboronic Acids


25 Certain protected organoboronic acid compounds comprising a boron having an sp^3 hybridization, a conformationally rigid protecting group bonded to the boron, and an organic group bonded to the boron through a boron-carbon bond; methods of making same; and methods of performing chemical reactions using same are disclosed in U.S. Patent Nos. 8,013,203, US 8,318,983, and US 2013/0296573, each to Burke et al., the entire contents of 30 which are incorporated herein by reference. Such compounds are represented generally by the following formula:



where R^{10} represents the organic group, B represents the boron having sp^3 hybridization, and R^{20} , R^{21} , R^{22} , R^{23} , and R^{24} independently are selected from the group consisting of a hydrogen group and an organic group.


5 In an embodiment, the protected organoboronic acid is a N-methyliminodiacetic acid (MIDA) boronate; i.e., R^{20} is methyl, and each of R^{21} , R^{22} , R^{23} , and R^{24} is hydrogen.

Protected organoboronic acids according to the foregoing formula may be prepared by reaction of an appropriate N-substituted imino-di-carboxylic acid with the corresponding unprotected boronic acid, as illustrated in the following reaction scheme:



10

In a specific example, protected organoboronic acids according to the foregoing formula may be prepared by reaction of N-methyliminodiacetic acid (MIDA) with the corresponding unprotected boronic acid, as illustrated in the following reaction scheme:




15

In each case, the protected organoboronic acid may be deprotected by contact with a mild aqueous base, to provide the free boronic acid.

Chiral Protected Organoboronic Acids


Certain protected organoboronic acid compounds comprising a boron having an sp^3 hybridization, a conformationally rigid protecting group bonded to the boron, a chiral first

organic group bonded to the protecting group, and a second organic group bonded to the boron through a boron-carbon bond; methods of making same; and methods of performing chemical reactions using same are disclosed in U.S. Patent Application Publication No. 2014/0094615 to Burke et al., the entire content of which is incorporated herein by reference. Such compounds are represented generally by the following formula:



where R¹⁰ represents the second organic group, B represents the boron having sp³ hybridization, R* represents the chiral first organic group, and R²¹, R²², R²³, and R²⁴ independently are selected from the group consisting of a hydrogen group and an organic group.

In certain embodiments, R* is a chiral group represented by



wherein:

R³¹ and R³² are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, and heteroaralkyl; or R³¹ and R³², taken together, form a 5-10-membered cycloalkyl or aromatic ring, or form a 5-10-membered heterocyclic or heteroaromatic ring comprising 1-3 heteroatoms independently selected from the group consisting of N, O, and S;

R³³ is selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, and heteroaralkyl; and


m is an integer 0, 1, or 2.

In certain embodiments, R* is a chiral group of at least 90 percent enantiomeric excess.


In certain embodiments, R²¹, R²², R²³, and R²⁴ are independently selected from the group consisting of hydrogen and (C₁-C₃)alkyl.

In an embodiment, R¹ and R², and/or R³ and R⁴, are independently selected from the group consisting of hydrogen and (C₁-C₃)alkyl.


In certain embodiments, R²¹, R²², R²³, and R²⁴ are hydrogen.




In one embodiment, R^* is




In one embodiment, R^* is



In one embodiment, R^* is




In one embodiment, R^* is selected from the group consisting of




5 and




In one embodiment, R^* is selected from the group consisting of




and




In one embodiment, R^* is selected from the group consisting of




and




In one embodiment, R^{31} and R^{32} , taken together, form a 5-10-membered cycloalkyl or aromatic ring, or form a 5-10-membered heterocyclic or heteroaromatic ring comprising 1-3 heteroatoms independently selected from the group consisting of N, O, and S.




In one embodiment, R^* is .




In one embodiment, R^* is .




In one embodiment, R^* is .



In one embodiment, R^* is .




In one embodiment, R^* is .




In one embodiment, R^* is .

Protected chiral organoboronic acids according to the foregoing formula may be prepared by reaction of an appropriate N-substituted imino-di-carboxylic acid with the corresponding unprotected boronic acid, as illustrated in the following reaction scheme:




In a specific example, chiral protected organoboronic acids according to formula (I) may be prepared by reaction of N-pinene-iminodiacetic acid (PIDA) with the corresponding unprotected boronic acid (V), as illustrated in the following reaction scheme:



In each case, the chiral protected organoboronic acid may be deprotected by contact with a mild aqueous base, to provide the free boronic acid.

Methods of the Invention

Achieving the targeted site- and stereo-retentive cross-coupling of unactivated chiral secondary boronic acids, e.g., **1a**, required concomitantly overcoming several major challenges (Scheme 1, FIG. 1), including: (i) *reactivity* – unactivated Csp^3 boronic acids are less reactive than their Csp^2 and activated Csp^3 counterparts; (ii) *site-retention* – a competing sequence of beta-hydride elimination followed by hydropalladation and reductive elimination from the less sterically hindered primary carbon-palladium bond typically generates undesired linear product **4** as a major byproduct; and (iii) *stereo-retention* – competitive retentive vs. invertive transmetalation^{3d} and/or an undesired sequence of beta-hydride elimination followed by hydropalladation and reductive elimination from a secondary carbon-palladium bond may cause loss of the stereochemical information present in the starting boronic acid.

Table 1. Efficient and site-retentive cross-coupling of **1a**.^a

entry	catalyst	added ligand	base	combined yield (%) ^b	3a:4a
1	Pd(PPh ₃) ₄	-	K ₂ CO ₃	0	-
2	Pd(PPh ₃) ₄	-	K ₃ PO ₄	0	-
3	Pd(PPh ₃) ₄	-	NaOH	0	-
4	Pd(PPh ₃) ₄	-	Ag ₂ O	81	1:1
5	Pd(dCypf)Cl ₂	-	Ag ₂ O	0	-
6	Pd(dt-Bupf)Cl ₂	-	Ag ₂ O	16	1:1
7	Pd(dppf)Cl ₂	-	Ag ₂ O	65	1:1
8	Pd(OAc) ₂	Cy ₃ P	Ag ₂ O	0	-
9	Pd(OAc) ₂	tBu ₃ P	Ag ₂ O	0	-
10	Pd(OAc) ₂	Bu ₂ MeP	Ag ₂ O	0	-
11	Pd(OAc) ₂	SPhos	Ag ₂ O	<5	-
12	Pd(OAc) ₂	XPhos	Ag ₂ O	<5	-
13	Pd(OAc) ₂	Ruphos	Ag ₂ O	0	-
14	Pd(OAc) ₂	P(o-tol) ₃	Ag ₂ O	47	>20:1
15	Pd(P(o-tol)₃)₂	-	Ag ₂ O	81	>20:1

^a Reaction conditions: 2 equiv. of **1**, 5 equiv. of base, 10 mol% catalyst, 20 mol% added ligand, THF, 85 °C, 24 h.

^b Yields obtained by ¹H NMR using hexamethylbenzene as an internal standard; average of two runs.

To address the first two of these problems (i.e., reactivity and site-retention), we pursued the cross-coupling of racemic unactivated secondary boronic acid (±)-**1a** with aryl halide **2a** (Table 1). Previous reports of similar couplings involved low to moderate yields and/or undesirable branched:linear ratios.^{4b-d} Consistent with the poor reactivity of secondary boronic acids, a series of standard catalyst and base combinations yielded no product (Table 1, entries 1-3). Silver(I) oxide has been shown to promote Suzuki-Miyaura reactions with primary alkyl boronic acids⁷ and activated secondary boronic esters.^{3a} We found that the combination of Pd(PPh₃)₄ and Ag₂O in THF promoted the reaction of **1** with

2a to generate an 86% yield of cross-coupling products, albeit as a 1:1 ratio of branched and linear isomers **3a** and **4a** (Table 1, entry 4).

Turning our attention to the problem of site-retention, we first tested ligand/Pd systems with the potential to accelerate the desired reductive elimination pathway.

5 However, bidentate phosphine ligands⁸ resulted in decreased yields and/or no improvement in site-selectivity (entries 5-7), and bulky trialkylphosphine ligands^{4a} did not yield any detectable product (entries 8-10). We also sought to disfavor the undesired β -hydride elimination pathway by employing ligands that might block the required agostic interaction between Pd and a β -hydrogen on the alkyl ligand (Scheme 1, **FIG. 1**). Buchwald-type
10 dialkyl biaryl phosphine ligands, which possess an *ipso*-interaction between the Pd center and the biaryl moiety on the ligand,⁹ and thus could theoretically achieve this goal, are ineffective in promoting the desired cross-coupling (entries 11-13). We also noted that a mechanistically analogous but undesirable β -hydride elimination pathway that competes during C-N cross-coupling with primary alkyl amines was suppressed by the use of Pd(P(*o*-tol)₃)₂,¹⁰ in which the *ortho*-methyl groups on the ligand may sterically block the required
15 open coordination site on Pd. Encouragingly, the addition of Pd(OAc)₂ and P(*o*-tol)₃ provided a 20:1 ratio of **3a**:**4a**, albeit in modest yield. Alternative employment of preformed Pd(P(*o*-tol)₃)₂,^{10b} an air-stable and commercially available complex, afforded both excellent reactivity and virtually complete site-retention (entry 15).

20 We next set out to determine the *stereochemical* course of this reaction by employing the unactivated secondary boronic acid **1a** in non-racemic form. To our knowledge, the stereochemical course for such a cross-coupling reaction has not been previously determined. We quickly recognized that two additional challenges have likely contributed to this lack of precedent: (i) *building block access* - methods are rare for
25 accessing unfunctionalized chiral boronic acids such as **1a** in non-racemic form;¹¹ and (ii) *stability* - secondary boronic acids can be quite unstable; e.g., the half-life of (\pm)-**1** in a vial on the benchtop under air is less than 24 hours.¹²

Building on our recently reported chiral iminodiacetic acid ligand platform,^{5j} we developed a simple and practical solution to both of these problems. Specifically, the
30 complexation of racemic 2-butyl boronic acid (\pm)-**1a** with 2-benzyloxycyclopentyl-derived iminodiacetic acid (BIDA) using PPTS in CH₃CN¹³ followed by trituration and recrystallization provides iminodiacetic acid boronate **5a** in highly diastereomerically enriched form (97:3 d.r., Scheme 2 (**FIG. 2**)). Like most MIDA boronates,⁵ BIDA boronate

5a is readily amenable to single crystal growth and X-ray analysis, enabling the stereochemistry at the boron-bearing carbon to be unambiguously assigned.^{12a} Moreover, in stark contrast to 1a, building block 5a is stable for *more than a year* on the benchtop under air.^{12a} It was further determined that highly pure and enantiomerically enriched (S)-1a can be prepared in nearly quantitative yield via the simple hydrolysis of 5a (Scheme 3 (FIG. 3)). This convenient new chiral building block, 5a, and the BIDA ligand will soon be commercially available.^{5z}

10 With robust and practical access to (S)-1a, we subjected this unactivated chiral nonracemic boronic acid to our optimized cross-coupling conditions and determined the stereochemical outcome via chiral HPLC analysis and comparison of optical rotation to literature precedent 14a (Scheme 3 (FIG. 3)). The desired product 3a was formed with an excellent level of stereo-retention.

Table 2. Efficient, site- and stereo-retentive cross-coupling of unactivated secondary boronic acids.^a

entry	secondary boronic acid (1)	halide (2)	product (3)	yield (%)	b:I ratio	stereo- retention (%)
1	(S)-1a	2b	3a	69	>20:1	91
2	(S)-1a	2c	3b	84	>20:1	88
3	(S)-1a	2d X = Br 2e X = I	3c	81 83	>20:1 >20:1	94 94
4	(S)-1a	2f	3d	82	>20:1	96
5	(S)-1a	2g X = Br 2h X = I	3e	0	-	-
6	(S)-1a	2i X = Br 2j X = I	3f	31 61	>20:1 >20:1	n.d. n.d.
7	1b	2a	3g	95	-	-
8	1c	2a	3h	95	-	-
9	1d	2a	3i	76	-	-
10	1e	2a	3j	69	-	-
11	(±)-1f	2a	(±)-3k	66	n.d.	-
12	(±)-1f	2e	(±)-3l	70	n.d.	-
13	(±)-1g	2a	(±)-3m	65	n.d.	-
14	(±)-1g	2e	(±)-3n	62	n.d.	-
15	(+)-1f	2a	(+)-3k	54	n.d.	99

^a Reaction conditions: 0.2 mmol of **1**, 0.1 mmol of **3**, 0.5 mmol of Ag_2O , 0.01 mmol of **Pd(P(o-tol)₃)₂**, THF, 85 °C, 24 h. The absolute stereochemistry of **3a** and **3b** were

determined by comparison of optical rotation to the corresponding literature values.¹⁴ The absolute stereochemistry of **3c-f** were assigned by analogy. b:l ratio = branched:linear ratio. n.d. = not determined.


5 We then completed a survey of the reaction scope (Table 2). Chiral nonracemic unactivated secondary boronic acid (*S*)-**1a** was coupled to both activated and non-activated aryl bromides and iodides (entries 1-5), with excellent to outstanding branched:linear ratios and stereo-retention. Electronic deactivation of the aryl halide is tolerated, as cross-coupling was achieved with para-*t*-butylbromobenzene **2i** (entry 8) and even more effectively with the corresponding iodide **2j** (entry 9). We found that a range of different cyclic secondary boronic acids are also excellent substrates (entries 10-17). Importantly, there is tolerance to increased steric bulk on the secondary boronic acid coupling partner, with *anti*-1-methyl-2-cyclopentylboronic acid (**1f**) and *anti*-1-methyl-2-cyclohexylboronic acid (**1g**)^{16a} reacting with activated and unactivated halides to yield the corresponding cross-coupling products **3k-3n** in good yields (entries 14-17). Finally, outstanding retention of stereochemical purity is maintained when boronic acid **1f** is employed in nonracemic form (entry 18).^{16b}

10

15

20 An aspect of the invention is a method of forming a product represented by R^1R^2CH-Ar , comprising:

combining a secondary boronic acid represented by $R^1R^2CH-B(OH)_2$; an aryl halide represented by $Ar-X$; a Pd catalyst; a ligand; and Ag_2O :



wherein, independently for each occurrence,

25 R^1 and R^2 are selected from the group consisting of substituted C_1-C_6 alkyl and unsubstituted C_1-C_6 alkyl; or R^1 and R^2 , taken together with the carbon to which they are joined, form a substituted or unsubstituted C_3-C_8 cycloalkyl;

Ar represents a substituted or unsubstituted monocyclic or polycyclic aryl;

X represents halogen;

30 Pd catalyst represents Pd(0) or Pd(II);

ligand is $P(o\text{-}R\text{-phenyl})_3$; and

R represents C₁-C₄ alkyl;

thereby forming a product represented by $R^1R^2CH\text{-Ar}$.

In certain embodiments, Pd catalyst represents Pd(0).

5 In certain embodiments, Pd catalyst represents Pd(II).

In certain embodiments, ligand is $P(o\text{-tol})_3$ (i.e., R is methyl).

In certain embodiments, the secondary boronic acid is achiral.

In certain embodiments, the secondary boronic acid is chiral.

In certain embodiments, the secondary boronic acid is a racemic mixture.

10 In certain embodiments, the secondary boronic acid is not a racemic mixture. The phrase “is not a racemic mixture” as used herein shall be understood to be equivalent to the phrase “is a non-racemic mixture”.

In certain embodiments, the secondary boronic acid has an enantiomeric excess of at least 80 percent. That is, in various individual embodiments, the secondary boronic acid has an enantiomeric excess of at least 80 percent, at least 81 percent, at least 82 percent, at least 83 percent, at least 84 percent, at least 85 percent, at least 86 percent, at least 87 percent, at least 88 percent, at least 89 percent, at least 90 percent, at least 91 percent, at least 92 percent, at least 93 percent, at least 94 percent, at least 95 percent, at least 96 percent, at least 97 percent, at least 98 percent, or at least 99 percent.

20 In certain embodiments, the secondary boronic acid has an enantiomeric excess of at least 90 percent.

In certain embodiments, the secondary boronic acid has an enantiomeric excess of at least 95 percent.

25 In certain embodiments, the product represented by $R^1R^2CH\text{-Ar}$ is not a racemic mixture.

In certain embodiments, the product represented by $R^1R^2CH\text{-Ar}$ has an enantiomeric excess of at least 80 percent.

In certain embodiments, the product represented by $R^1R^2CH\text{-Ar}$ has an enantiomeric excess of at least 90 percent.

30 In certain embodiments, the product represented by $R^1R^2CH\text{-Ar}$ has an enantiomeric excess of at least 95 percent.

In certain embodiments, R¹ and R² are selected from the group consisting of substituted C₁-C₆ alkyl and unsubstituted C₁-C₆ alkyl.

In certain embodiments, R¹ and R², taken together with the carbon to which they are joined, form a substituted or unsubstituted C₃-C₈ cycloalkyl.

In certain embodiments, Ar represents a substituted or unsubstituted phenyl.


In certain embodiments, Ar represents a substituted or unsubstituted polycyclic aryl.

5 In certain embodiments, X is Br.

In certain embodiments, X is I.

An aspect of the invention is a method of forming an air-stable chiral secondary boronic acid, wherein the air-stable chiral secondary boronic acid is not a racemic mixture, 10 comprising:

combining a chiral secondary boronic acid represented by formula (I)



wherein, independently for each occurrence, R¹ and R² are selected from the group 15 consisting of substituted C₁-C₆ alkyl and unsubstituted C₁-C₆ alkyl; a chiral iminodiacetic acid, wherein the chiral iminodiacetic acid is not a racemic mixture; a weak acid catalyst; and a polar aprotic solvent, thereby forming a mixture of chiral boronates;

resolving the mixture of chiral boronates into individual diastereomers; and

hydrolyzing an individual diastereomer,

20 thereby forming an air-stable chiral secondary boronic acid, wherein the air-stable chiral secondary boronic acid is not a racemic mixture.

In certain embodiments, the resolving is by crystallization.

In certain embodiments, the resolving is by chromatography.

In certain embodiments, the hydrolyzing is with aqueous hydroxide.

25 In certain embodiments, the hydrolyzing is with aqueous NaOH.

In certain embodiments, the chiral iminodiacetic acid has an enantiomeric excess of at least 80 percent. That is, in various individual embodiments, the chiral iminodiacetic acid has an enantiomeric excess of at least 80 percent, at least 81 percent, at least 82 percent, at least 83 percent, at least 84 percent, at least 85 percent, at least 86 percent, at 30 least 87 percent, at least 88 percent, at least 89 percent, at least 90 percent, at least 91

percent, at least 92 percent, at least 93 percent, at least 94 percent, at least 95 percent, at least 96 percent, at least 97 percent, at least 98 percent, or at least 99 percent.

In certain embodiments, the chiral iminodiacetic acid has an enantiomeric excess of at least 90 percent.

5 In certain embodiments, the chiral iminodiacetic acid has an enantiomeric excess of at least 95 percent.

In certain embodiments, the chiral iminodiacetic acid is benzylcyclopentyl iminodiacetic acid (BIDA).

10 In certain embodiments, the weak acid catalyst is pyridinium *p*-toluenesulfonate (PPTS).

In certain embodiments, the polar aprotic solvent is CH₃CN.

In certain embodiments, the chiral secondary boronic acid represented by formula (I) is a racemic mixture.

15 In certain embodiments, the chiral secondary boronic acid represented by formula (I) is not a racemic mixture.


In certain embodiments, the air-stable chiral secondary boronic acid has an enantiomeric excess of at least 80 percent. That is, in various individual embodiments, the air-stable chiral secondary boronic acid has an enantiomeric excess of at least 80 percent, at least 81 percent, at least 82 percent, at least 83 percent, at least 84 percent, at least 85 percent, at least 86 percent, at least 87 percent, at least 88 percent, at least 89 percent, at least 90 percent, at least 91 percent, at least 92 percent, at least 93 percent, at least 94 percent, at least 95 percent, at least 96 percent, at least 97 percent, at least 98 percent, or at least 99 percent.

20 In certain embodiments, the air-stable chiral secondary boronic acid has an enantiomeric excess of at least 90 percent.


In certain embodiments, the air-stable chiral secondary boronic acid has an enantiomeric excess of at least 95 percent.

30 An aspect of the invention is a method of forming an air-stable trihydroxyborate salt of a primary or secondary boronic acid, comprising:

(i) combining a primary or secondary boronate represented by formula (II):



a first polar aprotic solvent, and aqueous hydroxide, thereby forming a primary or secondary boronic acid represented by formula (I):



wherein, independently for each occurrence,

R^1 is selected from the group consisting of substituted $\text{C}_1\text{-C}_6$ alkyl and unsubstituted $\text{C}_1\text{-C}_6$ alkyl;

R^2 is selected from the group consisting of H, substituted $\text{C}_1\text{-C}_6$ alkyl and unsubstituted $\text{C}_1\text{-C}_6$ alkyl; and

R^a and R^b are selected from the group consisting of optionally substituted alkyl, aryl, and acyl; or R^a and R^b taken together with the $-\text{O}-\text{B}(\text{CHR}^1\text{R}^2)-\text{O}-$ moiety to which they are attached form an optionally substituted heterocyclic ring consisting of 5-10 heavy atoms in the backbone of said heterocyclic ring, wherein 3-5 heteroatoms selected independently from the group consisting of B, O, and N are present in said heterocyclic ring; and


(ii) combining the primary or secondary boronic acid represented by formula (I), an ether, and concentrated hydroxide, thereby forming an air-stable trihydroxyborate salt of a primary or secondary boronic acid.

In certain embodiments, the method further comprises combining the air-stable trihydroxyborate salt of a primary or secondary boronic acid, a Lewis acid, and a second polar aprotic solvent, thereby re-forming the primary or secondary boronic acid represented by formula (I).

In certain embodiments, the Lewis acid is BF_3OEt_2 .

In certain embodiments, the second polar aprotic solvent is dioxane.

In certain embodiments, the primary or secondary boronate represented by formula (II) is represented by formula (III):



wherein, independently for each occurrence,

5 R^1 is selected from the group consisting of substituted C_1 - C_6 alkyl, and
unsubstituted C_1 - C_6 alkyl;

10 R^2 is selected from the group consisting of H, substituted C_1 - C_6 alkyl, and
unsubstituted C_1 - C_6 alkyl;

 B represents boron having sp^3 hybridization; and

15 R^{20} , R^{21} , R^{22} , R^{23} , and R^{24} independently are selected from the group consisting of a
hydrogen group and an organic group.

 In certain embodiments, R^{21} , R^{22} , R^{23} , and R^{24} each represent a hydrogen group.

 In certain embodiments, the primary or secondary boronate represented by formula
(II) is achiral.


15 In certain embodiments, the primary or secondary boronic acid represented by
formula (I) is a primary boronic acid.

 In certain embodiments, the primary or secondary boronic acid represented by
formula (I) is a secondary boronic acid.

20 In certain embodiments, the air-stable salt of the primary or secondary boronic acid
is achiral.

 In certain embodiments, the primary or secondary boronate represented by formula
(II) is chiral.

 In certain embodiments, the primary or secondary boronate represented by formula
(II) is represented by formula (IV):



25 (IV).

In certain embodiments, the primary or secondary boronic acid represented by formula (I) is a primary boronic acid.

In certain embodiments, the primary or secondary boronic acid represented by formula (I) is a secondary boronic acid.

5 In certain embodiments, the secondary boronic acid is achiral.

In certain embodiments, the secondary boronic acid is chiral.

In certain embodiments, the chiral secondary boronic acid represented by formula (I) is a racemic mixture.

10 In certain embodiments, the chiral secondary boronic acid represented by formula (I) is not a racemic mixture.

In certain embodiments, the chiral primary or secondary boronate represented by formula (II) is a racemic mixture.

In certain embodiments, the chiral primary or secondary boronate represented by formula (II) is not a racemic mixture.

15 In certain embodiments, the chiral primary or secondary boronate represented by formula (II) has an enantiomeric excess of at least 80 percent.

In certain embodiments, the chiral primary or secondary boronate represented by formula (II) has an enantiomeric excess of at least 90 percent.

20 In certain embodiments, the chiral primary or secondary boronate represented by formula (II) has an enantiomeric excess of at least 95 percent.

In certain embodiments, the air-stable salt of the primary or secondary boronic acid is a chiral air-stable salt of the secondary boronic acid.

In certain embodiments, the chiral air-stable salt of the secondary boronic acid is a racemic mixture.

25 In certain embodiments, the chiral air-stable salt of the secondary boronic acid is not a racemic mixture.

In certain embodiments, the chiral air-stable salt of the secondary boronic acid has an enantiomeric excess of at least 80 percent.

30 In certain embodiments, the chiral air-stable salt of the secondary boronic acid has an enantiomeric excess of at least 90 percent.

In certain embodiments, the chiral air-stable salt of the secondary boronic acid has an enantiomeric excess of at least 95 percent.


In certain embodiments, the first polar aprotic solvent is tetrahydrofuran (THF).

In certain embodiments, the aqueous hydroxide is aqueous NaOH.

In certain embodiments, the ether is methyl *tert*-butyl ether (MTBE).

In certain embodiments, the concentrated hydroxide is concentrated NaOH.

5 An aspect of the invention is a method of forming a boronic acid, comprising the steps represented by:



wherein

R^a represents an organic group; and

10 MIDA represents N-methyliminodiacetic acid.

In certain embodiments, the weak acid catalyst is pyridinium *p*-toluenesulfonate (PPTS).

In certain embodiments, the first polar aprotic solvent and the second polar aprotic solvent are the same.

15 In certain embodiments, the first polar aprotic solvent is CH_3CN .

In certain embodiments, the base is NaOH.

In certain embodiments, the second polar aprotic solvent is tetrahydrofuran (THF).

In certain embodiments, the first polar aprotic solvent is CH_3CN , and the second polar aprotic solvent is THF.

20 In certain embodiments, the organic group is a chiral organic group; and the boronic acid $R^a-B(OH)_2$ is a chiral boronic acid.

In certain embodiments, the chiral organic group is a racemic mixture; and the chiral boronic acid is a racemic mixture.

25 In certain embodiments, the chiral organic group is not a racemic mixture; and the chiral boronic acid is not a racemic mixture.

In certain embodiments, the chiral organic group has an enantiomeric excess of at least 80 percent. That is, in various individual embodiments, the chiral organic group has an enantiomeric excess of at least 80 percent, at least 81 percent, at least 82 percent, at least 83 percent, at least 84 percent, at least 85 percent, at least 86 percent, at least 87 percent, at

least 88 percent, at least 89 percent, at least 90 percent, at least 91 percent, at least 92 percent, at least 93 percent, at least 94 percent, at least 95 percent, at least 96 percent, at least 97 percent, at least 98 percent, or at least 99 percent.

5 In certain embodiments, the chiral organic group has an enantiomeric excess of at least 90 percent.

In certain embodiments, the chiral organic group has an enantiomeric excess of at least 95 percent.

10 In certain embodiments, the chiral boronic acid has an enantiomeric excess of at least 80 percent. That is, in various individual embodiments, the chiral boronic acid has an enantiomeric excess of at least 80 percent, at least 81 percent, at least 82 percent, at least 83 percent, at least 84 percent, at least 85 percent, at least 86 percent, at least 87 percent, at least 88 percent, at least 89 percent, at least 90 percent, at least 91 percent, at least 92 percent, at least 93 percent, at least 94 percent, at least 95 percent, at least 96 percent, at least 97 percent, at least 98 percent, or at least 99 percent.

15 In certain embodiments, the chiral boronic acid has an enantiomeric excess of at least 90 percent.

In certain embodiments, the chiral boronic acid has an enantiomeric excess of at least 95 percent.

REFERENCES

20 (1) (a) Merrifield, R. B. *Science* 1965, 150, 178-185. (b) Caruthers, M. H. *Science* 1985, 230, 281-285. (c) Plante, O. J.; Palmacci, E. R.; Seeberger, P. H. *Science* 2001, 291, 1523-1527.

25 (2) (a) Metal-Catalyzed Cross-Coupling Reactions; Diederich, F., Stang, P. J., Eds.; Wiley-VCH: Weinheim, Germany, 1998; (b) Suzuki, A.; Brown, H. C. *Organic Synthesis via Boranes*; Aldrich: Milwaukee, WI, 2003. (c) Netherton, M. R.; Fu, G. C. In *Topics in Organometallic Chemistry: Palladium in Organic Synthesis*; Tsuji, J., Ed.; Springer: New York, 2005. (d) Glorius, F. *Angew. Chem., Int. Ed.* 2008, 47, 8347-8349. (e) Glasspoole, B. W.; Cradden, C. M. *Nat. Chem.* 2011, 3, 912-913. (f) Heravi, M. M.; Hashemi, E. *Tetrahedron* 2012, 68, 9145-9178. (g) Han, FS. *Chem. Soc. Rev.* 2013, 42, 5270-98.

30 (3) Recent advances in site- and/or stereo-retentive cross-coupling of activated secondary Csp³ organoboronates: (a) Imao, D.; Glasspoole, B. W.; Laberge, V. S.; Cradden, C. M. *J. Am. Chem. Soc.* 2009, 131, 5024-5025. (b) Sandrock, D. L.; Jean-Gérard, L.;

Chen, C.; Dreher, S. D., Molander, G. A. *J. Am. Chem. Soc.*, 2010, 132, 17108-17110.

(c) Ohmura, T.; Awano, T.; Suginome, M. *J. Am. Chem. Soc.*, 2010, 132, 13191–13193. (d) Awano, T.; Ohmura, T.; Suginome, M. *J. Am. Chem. Soc.* 2011, 133, 20738-20741. (e) Daini, M.; Suginome, M. *J. Am. Chem. Soc.* 2011, 133, 4758-4761.

5 (f) Molander, G. A.; Wisniewski, S. R. *J. Am. Chem. Soc.* 2012, 134, 16856-16868.

(4) Examples of cross-coupling of unactivated Csp^3 organoboronates without site- and/or stereocontrol: (a) Fu, *J. Am. Chem. Soc.* 2000, 122, 4020-4028. (b) Kataoka, N.; Shelby, Q.; Stambuli, J. P.; Hartwig, J. F. *J. Org. Chem.* 2002, 67, 5553-5566. (c) Dreher, S. D.; Dormer, P. G.; Sandrock, D. L.; Molander, G. A. *J. Am. Chem. Soc.* 2008, 130, 9257-9259. (d) van den Hoogenband, A.; Lange, J. H. M.; Terpstra, J. W.; Koch, M.; Visser, G. M.; Visser, M.; Korstanje, T. J.; Jastrzebski, J. T. B. H. *Tet. Lett.* 2008, 49, 4122-4124.

10 (5) (a) Gillis, E. P.; Burke, M. D. *Aldrichimica Acta* 2009, 42, 17-27. (b) Wang, C.; Glorius, F. *Angew. Chem., Int. Ed.* 2009, 48, 5240-5244. (c) Gillis, E. P.; Burke, M. D. *J. Am. Chem. Soc.* 2007, 129, 6716-6717. (d) Gillis, E. P.; Burke, M. D. *J. Am. Chem. Soc.* 2008, 130, 14084-14085. (e) Suk, J. L.; Gray, K. C.; Paek, J. S.; Burke, M. D. *J. Am. Chem. Soc.* 2008, 130, 466-468. (f) Knapp, D. M.; Gillis, E. P.; Burke, M. D. *J. Am. Chem. Soc.* 2009, 131, 6961-6963. (g) Lee, S. J.; Anderson, T. M.; Burke, M. D. *Angew. Chem., Int. Ed.* 2010, 49, 8860-8863. (h) Woerly, E. M.; Cherney, A. H.; Davis, E. K.; Burke, M. D. *J. Am. Chem. Soc.* 2010, 132, 6941-6943. (i) Fujii, S.; Chang, S. Y.; Burke, M. D. *Angew. Chem., Int. Ed.* 2011, 50, 7862-7864. (j) Li, J.; Burke, M. D. *J. Am. Chem. Soc.* 2011, 133, 13774-13777. (k) Dick, G. R.; Woerly, E. M.; Burke, M. D. *Angew. Chem., Int. Ed.* 2012, 51, 2667-2672. (l) Gray, K. C.; Palacios, D. S.; Dailey, I.; Endo, M. M.; Uno, B. E.; Wilcock, B. C.; Burke, M. D. *Proc. Natl. Acad. Sci.* 2012, 109, 2234-2239. (m) Fujita, K.; Matsui, R.; Suzuki, T.; Kobayashi, S. *Angew. Chem., Int. Ed.* 2012, 51, 7271-7274. (n) Grob, J. E.; Dechantsreiter, M. A.; Tichkule, R. B.; Connolly, M. K.; Honda, A.; Tomlinson, R. C.; Hamann, L. G. *Org. Lett.* 2012, 14, 5578-5581. (o) Grob, J. E.; Nunez, J.; Dechantsreiter, M. A.; Hamann, L. G. *J. Org. Chem.* 2011, 76, 10241-10248. (p) Grob, J. E.; Nunez, J.; Dechantsreiter, M. A.; Hamann, L. G. *J. Org. Chem.* 2011, 76, 4930-4940. (q) Dennis, E. G.; Jeffery, D. W.; Johnston, M. R.; Perkins, M. V.; Smith, P. A. *Tetrahedron* 2012, 68, 340-348. (r) He, Z.; Yudin A. K. *J. Am. Chem. Soc.* 2011, 133, 13770-13773. (s) Zhi, H.; Piera, T.; Shinya, A.; Jeffrey, D.S.D.; Yudin, A.K. *Angew.*

Chem., Int. Ed. 2012, 51, 11092-11096. (t) Wang, H.; Grohmann, C.; Nimphius, C.; Glorius, F. *J. Am. Chem. Soc.* 2012, 134, 19592-19595. (u) Delaunay, T.; Es-Sayed, M.; Vors, J.; Monteiro, N.; Balme, G. *Chem. Lett.* 2011, 40, 1434-1436. (v) Chan, J. M. W.; Amarante, G. W; Toste, F. D. *Tetrahedron* 2011, 67, 4306-4312. (w) Mohamed, Y. M. A.; Trond, V. H. *Tet. Lett.* 2011, 52, 1057-1059. (x) Brak, K.; Ellman, J. A. *Org. Lett.* 2010, 12, 2004-2007. (y) Willwacher, J.; Kausch-Busies, N.; Fürstner, A. *Angew. Chem., Int. Ed.* 2012, 51, 12041-12046. (z) >140 MIDA boronates are now commercially available from Sigma-Aldrich, St. Louis, MO.

(6) Lovering, F.; Bikker, J.; Humblet, C. *J. Med. Chem.* 2009, 52, 6752-6756.

10 (7) (a) Falck, J. R.; Kumar, P. S.; Reddy, Y. K.; Zou, G.; Capdevila, J. H. *Tet. Lett.* 2001, 42, 7211-7212. (b) Zou, G.; Reddy, Y. K.; Falck, J. R. *Tet. Lett.* 2001, 42, 7213-7215. (c) Barfoot, C. W.; Harvey, J. E.; Kenworthy, M. N.; Kilburn, J. P.; Ahmed, M.; Taylor, R. J. K. *Tetrahedron* 2005, 61, 3403-3417. (d) For an early report on the promoting effect of Ag_2O on Suzuki-Miyaura cross-coupling, see: Uenishi, J.; Beau, J. M.; Armstrong, R. W.; Kishi, Y. *J. Am. Chem. Soc.* 1987, 109, 4756-4758.

15 (8) Miyaura, N.; Ishiyama, T.; Ishikawa, M.; Suzuki, A. *Tet. Lett.* 1986, 27, 6369-6372.

(9) Martin, R.; Buchwald, S. L. *Acc. Chem. Res.* 2008, 41, 1461-1473.

20 (10) (a) Hartwig, J. F.; Richards, S.; Baranano, D.; Paul, F. *J. Am. Chem. Soc.* 1996, 118, 3626-3633. (b) Paul, F.; Patt, J.; Hartwig, J. F. *J. Am. Chem. Soc.* 1994, 116, 5969-5970.

(11) Brown, H. C.; Jadhav, P. K.; Desai, M. C. *J. Am. Chem. Soc.* 1982, 104, 4303-4304.

25 (12) (a) See supporting information. (b) Commercial (+/-)-1 was shipped in a sealed vial under argon.

(13) (a) Initial attempts to resolve 1a using our previously reported PIDA ligand **5j** were not successful. (b) These convenient reaction conditions (PPTS, CH_3CN , 80 °C) also readily promote synthesis of MIDA boronates from the corresponding boronic acids.


30 (c) During the preparation of this manuscript, a related resolution of racemic 1,1'-bi-2-naphthol boronic acid was reported: Lee, C.; Cheon, C. *J. Org. Chem.* 2013, 78, 7086-7092. (d) For an earlier report on enantioenrichment of boronic acids with chiral ligands, see: Brown, H. C.; Gupta, A. K. *J. Organomet. Chem.* 1988, 341, 73-81.

(14) The absolute stereochemistry of **3a** and **3b** were determined by comparison of the optical rotation to the corresponding literature values: (a) Menicagli, R., Piccolo, O. *J. Org. Chem.* 1980, 45, 2581-2585. (b) Piccolo, O.; Menicagli, R.; Lardicci,


L. *Tetrahedron* 1979, 35, 1751-1578. (c) Taylor, B. L. H.; Swift, E. C.; Waetzig, J. D.; Jarvo, E. R. *J. Am. Chem. Soc.* 2011, 133, 389-391.

(15) Molander, G.A.; Cavalcanti, L.N.; Canturk, B.; Pan, P.; Kennedy, L.E. *J. Org. Chem.* 2009, 74, 7364-7369.

5 (16) (a) Enabling fresh preparation of these boronic acids in excellent purity, we developed a novel method for direct transformation of trifluoroborate salts into the corresponding MIDA boronates, which in turn can be very efficiently hydrolyzed into the readily isolable corresponding boronic acids just prior to use in a reaction. Specifically, racemic **1f** and **1g** were prepared via direct transformation of commercially available trifluoroborate salts **6a** and **6b** into the corresponding MIDA boronates **7a** and **7b**.
10 These air- and chromatographically stable crystalline solids were then readily hydrolyzed to the corresponding boronic acids **1f** and **1g** prior to the cross-coupling reactions reported in Table 2.



15 (b) This methodology was extended using the BIDA ligand to prepare boronic acid **(+)-1f** in highly enantiomerically enriched form (see Example 14).



EXAMPLES

The disclosure may be further understood by the following non-limiting examples. Although the description herein contains many specific values, these should not be construed as limiting the scope of the disclosure, but as providing illustrations of some of 5 the embodiments of the disclosure. The scope of the disclosure should be determined by the appended claims and their equivalents, rather than by the examples given.

I. General Methods

Materials. Commercial reagents were purchased from Sigma-Aldrich, Fisher Scientific, Alfa Aesar, TCI America, or Frontier Scientific, and were used without further 10 purification unless otherwise noted.

Pd(P(*o*-tol)₃)₂ and Ag₂O were purchased from Sigma-Aldrich. A gift of Pd(P(*o*-tol)₃)₂ was donated by Johnson Matthey. Solvents were purified via passage through packed 15 columns as described by Pangborn and coworkers¹ (THF, Et₂O, CH₃CN, CH₂Cl₂; dry neutral alumina; hexane, benzene, and toluene, dry neutral alumina and Q5 reactant; DMSO, DMF: activated molecular sieves). All water was deionized prior to use.

Diisopropylethylamine was freshly distilled under an atmosphere of nitrogen from CaH₂.


General experimental procedures. Unless otherwise noted, all reactions were performed in flame-dried round bottom or modified Schlenk flasks fitted with rubber septa under a positive pressure of argon or nitrogen. Organic solutions were concentrated via 20 rotary evaporation under reduced pressure with a bath temperature of 23 °C unless otherwise noted. Reactions were monitored by analytical thin layer chromatography (TLC) performed using the indicated solvent on E. Merck silica gel 60 F254 plates (0.25 mm). Compounds were visualized by exposure to a UV lamp (λ = 254 nm), and/or a solution of KMnO₄ and/or a solution of p-anisaldehyde, followed by brief heating using a Varitemp 25 heat gun. Column chromatography was performed using Merck silica gel grade 9385 60 Å (230-400 mesh).

Structural analysis. ¹H NMR and ¹³C NMR spectra were recorded at 20 °C on Varian Unity 500, Varian Unity Inova 500NB, or Varian Unity 500 instruments. Chemical shifts (δ) are reported in parts per million (ppm) downfield from tetramethylsilane and 30 referenced to residual protium in the NMR solvent (benzene, δ = 7.16; CHCl₃, δ = 7.26; acetone, δ = 2.05, center line; DMSO δ = 2.50, center line) or to added tetramethylsilane (δ = 0.00). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, sept = septet, m = multiplet, b = broad, app =

apparent), coupling constant (*J*) in Hertz (Hz), and integration. Chemical shifts (δ) for ^{13}C NMR are reported in ppm downfield from tetramethylsilane and referenced to carbon resonances in the NMR solvent (benzene-d6, δ = 128.06, center line; CDCl_3 , δ = 77.0, center line; acetone-d6, δ = 39.5, center line; DMSO-d_6 δ = 39.52, center line). Carbons bearing boron substituents were not observed (quadrupolar relaxation). High resolution mass spectra (HRMS) were performed by Furong Sun, Elizabeth Eves and Dr. Haijun Yao at the University of Illinois School of Chemical Sciences Mass Spectrometry Laboratory.

II. Experimental Procedures

10 a. Synthesis of chiral racemic MIDA boronates and boronic acids



To a 40-mL sealed I-Chem vial under nitrogen was added racemic 2-butyl boronic acid (+/-)-1a (710 mg, 5 mmol), N-methyliminodiacetic acid (MIDA) (2.20 g, 15 mmol), 15 pyridinium *p*-toluenesulfonate (126 mg, 0.5 mmol) followed by acetonitrile (16.7 mL, 0.3 M for the borate). The reaction was sealed and allowed to stir at 80 °C for 12 hours. After cooling down, the mixture was passed through a pad of silica gel before concentration. The light brown solid mixture was then loaded onto a silica gel column and flushed with copious amount of Et_2O , the product was then eluted with straight EtOAc . Upon 20 concentration, the product was obtained as a crystalline white solid (949 mg, 89%).


^1H NMR (500 MHz, DMSO) δ 4.18 (d, *J* = 17.0, 1H), 4.16 (d, *J* = 17.0, 1H), 3.98 (d, *J* = 17.0, 2H), 2.87 (s, 3H), 1.47 (m, 1H), 1.03 (m, 1H), 0.88 (t, *J* = 7.5, 3H), 0.81 (d, *J* = 7.0, 3H), 0.67 (s, 1H).

25 ^{13}C NMR (126 MHz, DMSO) δ 169.1, 169.0, 62.3, 62.1, 45.4, 24.5, 13.8, 12.7.

HRMS (ESI+)

Calculated for $\text{C}_9\text{H}_{17}\text{BNO}_4$: 214.1251

Found: 214.1252



To a 40-mL sealed I-Chem vial under nitrogen was added racemic potassium *trans*-2-methylcyclohexyltrifluoro borate **6b** (1.02 g, 5 mmol), N-methyliminodiacetic acid (MIDA) (2.20 g, 15 mmol), pyridinium *p*-toluenesulfonate (126 mg, 0.5 mmol) and silica 5 gel (900 mg) followed by acetonitrile (16.7 mL, 0.3 M for the borate). The reaction was sealed and allowed to stir at 80 °C for 12 hours. After cooling down, the mixture was passed through a pad of silica gel before concentration. The light brown solid mixture was then loaded onto a silica gel column and flushed with copious amount of Et₂O, the product was then eluted by straight EtOAc. Upon concentration, the product **7b** was obtained as a 10 crystalline white solid (1.17 g, 93%).

¹H NMR (499 MHz, DMSO) δ 4.17 (d, J = 17.0, 1H), 4.10 (d, J = 17.0, 1H), 3.98 (d, J = 17.0, 1H), 3.93 (d, J = 17.0, 1H), 2.89 (s, 3H), 1.66-1.56 (m, 4H), 1.44 (m, 1H) 1.24 (m, 1H), 1.15 (m, 1H), 1.09-0.96 (m, 2H), 0.95 (d, J = 6.5, 3H), 0.47 (m, 1H).

¹³C NMR (126 MHz, DMSO) δ 169.2, 168.7, 62.3, 62.0, 45.3, 36.3, 32.2, 26.5, 26.1, 25.3, 22.7.


HRMS (ESI+)

Calculated for C₁₂H₂₁BNO₄: 254.1564

Found: 254.1554

20

General procedure of hydrolysis of MIDA boronate




To a stirred solution of MIDA boronate (0.25 mmol) in 2 mL THF under argon was added 2 mL 1 M solution of NaOH. The reaction was allowed to stir at 23 °C for 0.5 h before 4 mL saturated aqueous NH₄Cl was added. Layers were separated and the aqueous layer was extracted with Et₂O three times. The combined ethereal layers were concentrated to near dry (complete dryness might lead to decomposition) and was re-extracted (a small

portion of brine could be added if necessary) with Et_2O three times before drying over Na_2SO_4 and concentrating to around 200 μL under reduced pressure. The solution was diluted with THF and dried with Na_2SO_4 again before concentration to a waxy solid to afford the boronic acid in quantitative yield (0.25 mmol).


5

b. Synthesis of enantiomerically-enriched boronic acid (*S*)-**1a**



The preparation of benzylcyclopentyl iminodiacetic acid (BIDA) followed the procedure developed previously in our group (Li, J., Burke, M.D. *J. Am. Chem. Soc.*, 2011, 133, 13774).

10



To a 40-mL sealed I-Chem vial under nitrogen was added racemic 2-butyl boronic acid (+/-)-**1a** (6 mmol), BIDA (4 mmol), pyridinium *p*-toluenesulfonate (0.4 mmol) followed by acetonitrile (27 mL, 0.15 M for **5**). The reaction was allowed to stir at 80 °C for 24 hours. After cooling down, the mixture was passed through a pad of Florisil® before concentration. The light brown solid mixture was then dissolved in Et_2O to make a heterogeneous mixture and filtered; the filtrate was washed with copious amount of Et_2O . The white solid was recrystallized with acetone: Et_2O twice to give **5a** [463 mg, 97:3 d.r. (^1H NMR) 31%].

15

20 TLC: (hexanes: EtOAc = 1:1, KMnO_4)

R_f = 0.41, (*S*) isomer **5a**; R_f = 0.16, (*R*) isomer **5b**


^1H NMR (500 MHz, DMSO) δ 8.19 (m, 4H), 8.14 (m, 1H), 5.36 (d, J = 11, 1H), 5.30 (d, J = 11, 1H), 5.03-4.90 (m, 4H), 4.77 (d, J = 17, 1H), 4.35 (q, J = 6, 1H), 4.17 (s, 3H), 2.89 (m, 1H), 2.83 (m, 1H), 2.83 (m, 1H), 2.26 (m, 1H), 1.90 (m, 1H), 1.69 (t, J = 3H), 1.66-1.58 (m, 3H).

¹³C NMR (125 MHz, DMSO-d6) δ 169.8, 168.3, 137.9, 128.3, 127.8, 127.6, 79.8, 72.1, 70.9, 59.3, 56.4, 39.5, 29.4, 26.2, 24.9, 21.0, 14.2, 12.6.


HRMS (ESI+)

Calculated for C₂₀H₂₉BNO₅: 374.2139

5 Found: 374.2119




To a stirred solution of **7** (93 mg, 0.25 mmol) in 2 mL THF under argon was added 2 mL 1 M solution of NaOH. The reaction was allowed to stir at 23 °C for 0.5 h before 4 mL saturated aqueous NH₄Cl was added. Layers were separated and the aqueous layer was extracted with Et₂O three times. The combined ethereal layers were concentrated to near dry (complete dryness might lead to decomposition) and was re-extracted (a small portion of brine could be added if necessary) with Et₂O three times before drying over Na₂SO₄ and concentrating to around 200 µL under reduced pressure. The solution was diluted with THF and dried with Na₂SO₄ again before concentration to a waxy solid to afford (*S*)-**1a** (25 mg, 100%).



*absolute stereochemistry of **5c** at C1 and C2 have not been determined


c. General procedure of coupling reactions of aryl halides with alkyl boronic acids



In the glove box under argon atmosphere, aryl halide (0.10 mmol), boronic acid (0.20 mmol), Ag_2O (70 mg, 0.30 mmol) and $\text{Pd}(\text{P}(o\text{-tol})_3)_2$ (7.15 mg, 0.010 mmol) were taken up in THF (220 μL) in a 7-mL vial. The reaction was sealed, and stirred at 85 °C for 24 h. The mixture was then passed through a pad of silica gel and flushed with diethyl ether before concentration *in vacuo*. The desired product was isolated by column chromatography and/or preparative reverse-phase HPLC.

Cross-coupling reactions of aryl halides with alkyl boronic acids

10 **Example 1. (S)-methyl 4-(sec-butyl)benzoate (3a)**



Product was isolated as a colorless oil (Br-, 71%; I-, 69%)

Enantiomeric ratio (Br-, 85:15, a 88% retention of e.r.; I-, 89:11, a 91% retention of e.r.) was determined by chiral-GC (CP chiral-DEX CB Column)

15 ^1H NMR (500 MHz, Benzene) δ 8.15 (d, J = 8.5, 2H), 6.96 (d, J = 8.0, 2H), 3.52 (s, 3H), 2.33 (m, 1H), 1.37 (m, 2H), 1.02 (d, J = 7.0, 3H), 0.68 (t, J = 7.5, 3H).

^{13}C NMR (126 MHz, Benzene-d6) δ 166.8, 153.0, 130.2, 127.4, 51.5, 41.9, 31.1, 21.7, 12.3.

HRMS (EI+)


20 Calculated for $\text{C}_{12}\text{H}_{16}\text{O}_2$: 192.1150

Found: 192.1141

The e.r. was determined by chiral-GC using a CP chiral-DEX CB Column (30 m x 320 μm x 0.25 μm). Conditions: 75 °C, 10 min; 5 °C/min to 105 °C and hold, flow rate = 1.2255 mL/min, detection wavelength = 214 nm. tr(major) 28.5 min, tr(minor) 29.1 min.

25

Example 2. (S)-2-(sec-butyl)naphthalene (3b)



Product was isolated as a colorless oil (Br-, 84%)

Enantiomeric ratio (Br-, 85:15, a 88% retention of e.r.) was determined by SFC analysis (OD-H Column)

¹H NMR (499 MHz, Benzene) δ 7.67 (m, 3H), 7.52 (s, 1H), 7.28 (m, 2H), 7.21 (dd, *J* = 8.0, 1.5, 1H), 2.595 (m, 1H), 1.60 (m, 1H), 1.54 (m, 1H), 1.23 (d, *J* = 7.0, 3H), 0.80 (t, *J* = 7.5, 3H).

¹³C NMR (126 MHz, Benzene) δ 145.1, 134.4, 132.9, 126.1, 126.0, 125.8, 125.4, 42.2, 31.3, 22.1, 12.5.


HRMS (EI+)

Calculated for C₁₄H₁₆: 184.1250

Found: 184.1249

The e.r. was determined by SFC analysis (OD-H Column) Conditions: 100% CO₂, flow rate = 2.0 mL/min. detection wavelength = 220 nm. tr(major) 9.4 min, tr(minor) 10.3 min.

15 Example 3. (S)-4-(sec-butyl)-1,1'-biphenyl (3c)



Product was isolated as a colorless oil (Br-, 81%; I-, 83%)

Enantiomeric ratio (Br-, 92:8, a 94% retention of e.r.; I-, 92:8, a 94% retention of e.r.) was determined by SFC analysis (OD-H Column)

¹H NMR (500 MHz, Benzene-d6) δ 7.53 (d, *J* = 7.0, 2H), 7.49 (d, *J* = 8.0, 2H), 7.24 (t, *J* = 8.2, 2H), 7.12 (d, *J* = 8.0, 2H), 2.48 (m, 1H), 1.53 (m, 2H), 1.19 (d, *J* = 7.0, 3H), 0.81 (t, *J* = 7.5, 3H).


¹³C NMR (125 MHz, Benzene-d6) δ 146.8, 141.8, 139.4, 129.0, 127.5, 127.4, 127.2, 41.7, 31.5, 22.1, 12.5.

HRMS (EI+)

Calculated for C₁₆H₁₈: 210.1409

Found: 210.1414

The e.r. was determined by SFC analysis (OD-H Column) Conditions: 100% CO₂, flow rate = 2.0 mL/min. detection wavelength = 220 nm. tr(major) 12.3 min, tr(minor) 15.8 min.

Example 4. (S)-3-(sec-butyl)-1,1'-biphenyl (3d)

Product was isolated as a colorless oil (Br-, 82%)

5 Enantiomeric ratio (Br-, 93:7, a 96% retention of e.r.) was determined by SFC analysis (OD-H Column)

¹H NMR (499 MHz, Benzene) δ 7.54 (m, 2H), 7.43 (t, *J* = 2.0, 1H), 7.38 (m, 1H), 7.24 (t, *J* = 15.5, 3H), 7.06 (m, 1H), 2.50 (m, 1H), 1.55 (m, 1H), 1.49 (m, 1H), 1.19 (d, *J* = 7.0, 3H), 0.80 (t, *J* = 7.5, 3H).

¹³C NMR (126 MHz, Benzene) δ 148.3, 142.2, 141.9, 129.2, 129.0, 127.7, 127.4, 126.5, 126.3, 125.3, 42.2, 31.5, 22.2, 12.5.

HRMS (EI+)

Calculated for C₁₆H₁₈: 210.1409

Found: 210.1410

15 The e.r. was determined by SFC analysis (OD-H Column) Conditions: 100% CO₂, flow rate = 2.0 mL/min. detection wavelength = 220 nm. tr(major) 12.3 min, tr(minor) 15.8 min.

Example 5. (S)-1-(sec-butyl)-4-(tert-butyl)benzene (3f)

20 Product was isolated as a colorless oil (Br-, 31%; I-, 61%)

¹H NMR (499 MHz, Benzene) δ 7.31 (d, *J* = 8.5, 2H), 7.11 (d, *J* = 8.5, 2H), 2.489 (m, 1H), 2.47 (m, 1H), 1.504 (m, 1H), 1.258 (s, 9H), 1.20 (d, *J* = 7.0, 3H), 0.81 (t, *J* = 7.5, 3H).


¹³C NMR (126 MHz, Benzene) δ 148.6, 144.7, 127.1, 125.5, 41.6, 34.4, 31.6, 31.6,

25 22.3, 12.5.

HRMS (EI+)

Calculated for C₁₂H₂₂: 190.1722

Found: 190.1727

Example 6. Methyl 4-cyclopropylbenzoate (**3g**)

Product was isolated as a colorless oil (Br-, 95%)

¹H NMR (499 MHz, Benzene) δ 8.09 (d, *J* = 8.5, 2H), 6.79 (d, *J* = 8.0, 2H), 3.52 (s, 5 H), 1.53-1.48 (m, 1H), 0.66-0.63 (m, 2H), 0.47-0.44 (m, 2H).


¹³C NMR (126 MHz, Benzene) δ 166.8, 149.8, 130.1, 125.7, 51.5, 51.5, 15.9, 10.3.

HRMS (EI+)

Calculated for C₁₁H₁₂O₂: 176.0837

Found: 176.0834

10

Example 7. Methyl 4-cyclobutylbenzoate (**3h**)

Product was isolated as a colorless oil (Br-, 95%)


¹H NMR (500 MHz, Benzene) δ 8.17 (d, *J* = 8.0, 2H), 6.99 (D, *J* = 8.0, 2H), 3.52 (s, 15 H), 3.22 (quint, *J* = 9.0, 1H), 2.09-2.02 (m, 2H), 1.94-1.85 (m, 2H), 1.81-1.71 (m, 1H), 1.66-1.58 (m, 1H).

¹³C NMR (126 MHz, Benzene) δ 166.8, 151.5, 130.0, 128.5, 126.6, 51.5, 40.5, 29.7, 18.5.

HRMS (EI+)

Calculated for C₁₂H₁₄O₂: 190.0994

Found: 190.0992

Example 8. Methyl 4-cyclopentylbenzoate (**3i**)

Product was isolated as a colorless oil (Br-, 76%)

¹H NMR (499 MHz, Benzene) δ 8.16 (d, *J* = 8.0, 2H), 7.04 (d, *J* = 8.5, 2H), 3.53 (s, 3H), 2.73-2.65 (m, 1H), 1.84-1.77 (m, 2H), 1.63-1.55 (m, 2H), 1.50-1.41 (m, 2H), 1.40-1.32 (m, 2H).

5 ¹³C NMR (126 MHz, Benzene) δ 166.8, 152.0, 130.1, 127.5, 51.5, 51.5, 46.2, 34.7, 25.8.


HRMS (EI+)

Calculated for C₁₃H₁₆O₂: 204.1150

Found: 204.1147

10

Example 9. Methyl 4-cyclohexylbenzoate (**3j**)



Product was isolated as a colorless oil (Br-, 69%)

15 ¹H NMR (499 MHz, Benzene) δ 8.17 (d, *J* = 8.5, 2H), 7.01 (d, *J* = 8.5, 2H), 3.53 (s, 3H), 2.27 (m, 1H), 1.66 (m, 4H), 1.63-1.59 (m, 1H), 1.24-1.17 (m, 5H).


¹³C NMR (126 MHz, Benzene) δ 166.8, 153.3, 130.2, 127.2, 51.5, 44.8, 34.3, 27.0, 26.3.

20 HRMS (EI+)

Calculated for C₁₄H₁₈O₂: 218.1307

Found: 204.1309

Example 10. Methyl 4-((1*S*,2*S*)-2-methylcyclopentyl)benzoate ((±)-**3k**)



25 ¹H NMR (500 MHz, Benzene) δ 8.17 (d, *J* = 8.5, 2H), 7.02 (d, *J* = 8.5, 2H), 3.53 (s, 3H), 2.20-2.14 (m, 1H), 1.90-1.77 (m, 2H), 1.73-1.64 (m, 1H), 1.61-1.48 (m, 3H), 1.17-1.09 (m, 1H), 0.82 (d, *J* = 6.5, 3H).


¹³C NMR (126 MHz, Benzene) δ 166.8, 151.0, 130.2, 54.7, 51.5, 43.3, 35.4, 35.0, 24.1, 18.5.

HRMS (EI+)

Calculated for C₁₄H₁₈O₂: 218.1307

Found: 218.1306

5 **Example 11.** 4-((1*S*,2*S*)-2-methylcyclopentyl)-1,1'-biphenyl ((±)-3l)



¹H NMR (500 MHz, Benzene) δ 7.55 (m, 2H), 7.51 (m, 2H), 7.24 (m, 2H), 2.34-2.28 (m, 1H), 2.05-1.99 (m, 1H), 1.92-1.80 (m, 2H), 1.73-1.59 (m, 3H), 1.25-1.19 (m, 1H), 0.94 (d, *J* = 6.0, 3H).

10 ¹³C NMR (126 MHz, Benzene) δ 144.6, 141.8, 139.5, 129.1, 127.6, 127.4, 127.3, 54.6, 43.3, 35.7, 35.0, 24.2, 18.7.


HRMS (EI+)

Calculated for C₁₈H₂₀: 236.1565

Found: 236.1565

15

Example 12. Methyl 4-((1*S*,2*S*)-2-methylcyclohexyl)benzoate ((±)-3m)



Product was isolated as a colorless oil (Br-, 65%)


20 ¹H NMR (500 MHz, Benzene) δ 8.16 (d, *J* = 8.5, 2H), 6.97 (d, *J* = 8.5, 2H), 3.53 (s, 3H), 1.88 (td, *J* = 11.0, 3.0, 1H), 1.68-1.61 (m, 4H), 1.38-1.30 (m, 1H), 1.28-1.12 (m, 3H), 0.97-0.88 (m, 1H), 0.61 (d, *J* = 6.5, 3H).

¹³C NMR (126 MHz, Benzene) δ 166.8, 152.3, 130.2, 128.8, 128.1, 52.7, 51.4, 37.6, 35.9, 35.5, 27.1, 26.9, 20.9.

HRMS (EI+)

25 Calculated for C₁₅H₂₀O₂: 232.1463

Found: 232.1466


Example 13. 4-((1*S*,2*S*)-2-methylcyclohexyl)-1,1'-biphenyl ((\pm)-3n)

Product was isolated as a colorless oil (I-, 62%)

¹H NMR (499 MHz, Benzene) δ 7.55 (m, 1H), 7.53 (m, 1H), 7.51 (d, J = 8.5, 2H),
 7.24 (m, 2H), 7.13 (m, 3H), 2.01 (td, J = 11.0, 3.5, 1H), 1.83 (m, 1H), 1.76-1.69 (m, 3H),
 1.54-1.45 (m, 1H), 1.44-1.22 (m, 3H), 1.06-0.97 (m, 1H), 0.76 (d, J = 6.5, 3H).
¹³C NMR (126 MHz, Benzene) δ 146.2, 141.8, 139.4, 129.0, 127.5, 127.4, 127.2,
 52.5, 38.0, 36.1, 36.0, 27.3, 27.1, 21.1.

HRMS (EI+)

Calculated for C₁₉H₂₂: 250.1721
 Found: 250.1724

Example 14.

*absolute stereochemistry of **5c** at C1 and C2 have not been determined

Product (+)-3k was isolated as a colorless oil (54%).

Enantiomeric ratio (Br-, 97:3, a 99% retention of e.r.) was determined by chiral-GC (CP chiral-DEX CB Column)

The e.r. was determined by chiral-GC using a CP chiral-DEX CB Column (30 m x 320 μ m x 0.25 μ m).


Conditions: 75 °C, 10 min; 1 °C/min to 120 °C and hold, flow rate = 1.2255 mL/min, detection wavelength = 214 nm. tr(major) 70.2 min, tr(minor) 73.3 min.

The optical rotation of (+)-1f was determined to be $[\alpha]^{23}\text{D}$ +14.4 (THF, e.e. = 94% based on **5b**). The optical rotation of (+)-3k was determined to be $[\alpha]^{23}\text{D}$ +46.0 (benzene, e.e. = 94% based on chiral-GC).

d. Determination of the absolute stereochemistry of **3a** and **3b**


The absolute stereochemistry of compounds **3a-3c** was determined by comparison of the optical rotation to the literature value. All products correspond to net retention in the cross-coupling reaction.

5



(*S*)-**3a**, $[\alpha]^{23}_D +21.0$ (EtOH, e.e. = 78% based on chiral GC)

lit: (*R*)-**3a**, $[\alpha]^{25}_D -19.02$ (EtOH, e.e. = 65%)(Menicagli R., Piccolo, O. *J. Org. Chem.*, **1980**, *45*, 2581)



(*S*)-**3b**, $[\alpha]^{23}_D +24.5$ (benzene, e.e. = 70% based on SFC)

lit: (*R*)-**3b**, $[\alpha]^{23}_D +33.3$ (neat, e.e. = 94%)((a) Piccolo, O. et al.

Tetrahedron **1979**, *35*, 1751; (b) Taylor, B.L. et al. *J. Am. Chem. Soc.* **2011**, *133*, 389)

10 III. Determination of Benchtop Stability of Boronic Acids and MIDA Boronates (Table 1)

The stability of 2-butyl boronic acid and 2-butyl BIDA boronates to storage as solids under air at 23 °C was quantified using the following general procedure: Two 7-mL vials were charged with 10 mg of freshly prepared boronic acid or BIDA boronate at 23 °C under ambient atmosphere. The vials containing these solid samples were then sealed with PTFE-lined screwcaps under ambient atmosphere and placed on the bench top at 23 °C.

15 The solid sample present in one of the vials was then immediately analyzed by ¹H-NMR to verify the purity and quantity of boronic acid present at time zero (the NMR assay is described below). After 1 day (boronic acid) or 60 days (BIDA boronates), the solid sample in the second vial was analyzed by ¹H-NMR, again by the method described below, to determine the quantity of boronic acid remaining at the indicated time.

20 NMR assay: An NMR stock solution was prepared as follows: To a 25 mL volumetric flask was added bromoacetophenone (0.336 g, 1.69 mmol, internal standard for quantification of the boronic acid), tetramethylsilane (1 mL, internal standard for the NMR


shifts), and DMSO-d6:D₂O 95:5 to a final solution volume of 25.0 mL. To a vial containing solid boronic acid or solid BIDA boronate (see above) was added 1.00 mL of this NMR stock solution, and the resulting solution was analyzed by ¹H-NMR. The mmol of boronic acid or MIDA boronate present in the sample was determined by comparing the ratio of the integrated 4-bromoacetophenone aryl C–H doublets (7.90 ppm relative to TMS) to that of the boronic acid or MIDA boronate C–H signals.

IV. Direct Conversion to Trihydroxyboronate Salt

In another embodiment, racemic secondary alkylboronic acids such as **1a** undergo complexation with the chiral derivative of iminodiacetic acid, **8**. The resulting diastereomers are resolved by recrystallization. Chiral boronate **5a** is then converted to the sodium trihydroxyborate salt **12**. Salt **12** was found to be stable to isolation and storage at room temperature, unlike the unstable boronic acid **1a**. By treating **12** with BF_3OEt_2 , **1a** is obtained as a dioxane solution a form that is competent for cross-coupling. This procedure was found to be highly reproducible, giving nonracemic **1a** in a pure form that is competent for cross-coupling, containing no oligomerized boroxine or other impurities resulting from degradation of **1a**. We then demonstrate stereoretentive Suzuki cross-coupling of **1a** to obtain representative chiral aromatic compounds **3a** and **3c** in enantioenriched form.

Example 15.


Step 1.



(1S,2S)-(+)-2-Benzyl-2-benzyloxycyclopentylamine, 99% ee: 957 mg (5 mmol), benzyl bromoacetate, 96%: 2.74 g (11.5 mmol), K_2CO_3 : 3.36 g (24.3 mmol), MeCN: 17 mL


To a 3-neck flask containing K_2CO_3 and a stir bar, and fitted with a reflux condensor, added MeCN, then substrate **10**, then benzyl bromoacetate. The mixture was stirred at 45 °C under nitrogen. After 16 hours, full conversion seen by TLC using 100% EtOAc and KMnO_4 stain. The mixture was filtered through Celite with EtOAc washings

and concentrated by rotary evaporation. The resulting yellow oil was purified by silica gel chromatography using a gradient of 10% to 30% EtOAc in hexanes. **11** was collected and concentrated under vacuum for 16 hours to 2.23 g viscous oil, 91%.



substrate **11**: 2.44 g (5 mmol), 10% Pd on carbon: 1.2 g, 1,4-cyclohexadiene: 4.9 mL (50 mmol), absolute EtOH: 50 mL

To a 3-neck flask containing palladium on carbon and a stir bar under nitrogen, added 40 mL EtOH, then **11**. The substrate was transferred with an additional 10 mL of EtOH. Added cyclohexadiene by syringe. Stirred at room temperature. The reaction exothermed to 30 °C. The reaction was complete at 2 hours as seen by TLC using 1:4 H₂O:acetone and cerium ammonium molybdate stain. 100 mL of MeOH was added to dissolve the white precipitate. The catalyst was filtered off by passing the mixture through Celite while keeping under N₂ and washing through with EtOH. The flow-through was concentrated by rotary evaporation to 1.4 g of **8** as a white solid, 91%. No purification was necessary.




2-butylboronic acid: 2.80 g (27.5 mmol), **3**: 7.04 g (22.9 mmol), DMSO: 23 mL, toluene: 207 mL

Racemic **1a**, obtained from Sigma Aldrich, was combined with DMSO, toluene, and **8** in a round-bottom flask with a stir bar. The flask was fitted with a Dean-Stark trap and reflux condenser. The mixture was stirred at reflux in an oil bath at 170 °C under air with continuous removal of water. After 3 hours, conversion was complete by TLC using 1:1

EtOAc:hexanes and KMnO₄ stain. The toluene was removed by rotary evaporation. 200 mL of DCM and 200 mL were added to the resulting DMSO suspension. In a separatory funnel, the aqueous layer was extracted four times with DCM. The combined DCM phase was washed with water five times, then once with brine. It was then dried with sodium sulfate and concentrated by rotary evaporation. The resulting solid was dissolved in acetone and passed through silica in a glass frit. The flow-through was again concentrated under vacuum. The crude **5**, 1:1 dr, was dissolved in 40 mL of dry acetone with heating. 80 mL of Et₂O was slowly added to this stirred solution, causing a white precipitate. This was stirred 10 hours and the solids were filtered. This white solid, 2.55 g, was dissolved in 17 mL acetone. 34 mL Et₂O was slowly added, causing precipitation. The suspension was stirred 5 hours, then the solids were collected by filtration. 1.79 g of **5a** was obtained as a white solid. 21% yield. ¹H-NMR in CDCl₃ showed a diastereomeric ratio of 99:1. The absolute stereochemistry of the 2-butyl stereocenter was determined by x-ray crystallography.

Compound **8** was recovered from the combined concentrated flow-through from the above procedure. The combined solid, 6.64 g, was combined with 12 mL of 3 M NaOH and 12 mL THF and stirred at room temperature until complete hydrolysis was seen by TLC. The THF was removed under rotary evaporation. 8.5 mL of saturated NH₄Cl was added. In a separatory funnel, this solution was washed three times with 15 mL of Et₂O. The Et₂O residue was removed under an air stream, then the solution was acidified to pH 3 with 6 M HCl, causing precipitation to form. The suspension was stirred in an ice bath for 1 hour, then the solids were collected by filtration and dried under vacuum to give 4.04 g of recovered **8**.

25 Step 2.



5a: 747 mg (2 mmol), THF: 10 mL, 1 M NaOH: 10 mL, saturated NH₄Cl: 10 mL, MTBE: 40 mL, 50% NaOH: 106 μ L (2 mmol)


5 **5a** was stirred in a round-bottom flask with 10 mL THF and 10 mL NaOH until complete conversion as seen by TLC using 1:1 EtOAc:Hexanes and KMnO₄ stain. THF was thoroughly removed under rotary evaporation with 40 °C bath. 10 mL of saturated NH₄Cl was added and the solution was extracted four times with 10 mL of MTBE in a separatory funnel. The combined MTBE phase was dried over Na₂SO₄ and concentrated by rotary evaporation to a volume of 10 mL. To this solution was added 106 μL of 50% NaOH over 1 minute with rapid stirring. The suspension was stirred 20 minutes at room temperature, then the solids were collected by filtration through a medium glass frit. The solids were washed with 2 mL of MTBE and dried under vacuum at 1 torr for 12 hours to give **12** in 88% yield as a white solid.

10

15 **12** was analyzed by NMR by the following procedure. 14.2 mg (0.1 mmol) of **12** was added to an NMR tube with 500 μL of CD₃OD containing 0.1 M 1,4-dimethoxybenzene as an internal standard. ¹H-NMR was taken with the d1 parameter set to 10 seconds. The hydroxyl peak appears at 4.95 ppm. The signals of the standard were integrated to 4H and 6H. A second spectrum of 500 μL of CD₃OD was taken and the signals of the standard were integrated to 4H and 6H. The integration of the hydroxyl peak and 4.95 ppm was subtracted from the corresponding peak in the spectrum of **12**. The value obtained was 2.7H, indicating no excess water or sodium hydroxide present in the sample of **12**.

20

Step 3.




12: 114 mg (0.8 mmol), **BF₃OEt₂:** 99 μL (1.4 mmol), **1,4-dioxane:** 0.6 mL

25 **12** was added to a 2 mL vial with 400 μL dioxane and a stir bar. In the hood, the vial was opened to the air and BF₃OEt₂ was added over 1 minute with 1300 rpm stirring. The vial was capped and stirred 30 minutes at room temperature. The slurry was filtered through 40 mg of Celite over a cotton plug in a 5 inch Pasteur pipette. The vial was washed with 200 μL dioxane and passed through the Celite with an air hose, giving 440 μL of solution. 50 μL of the homogeneous dioxane solution was withdrawn and added to 500 μL of DMSO-d₆ containing 0.1 M 1,4-dimethoxybenzene standard. ¹H-NMR with d1 set to 10

30


seconds showed the concentration of the boronic acid **1a** to be 1.32 M. Yield was calculated to be 72%.

Step 4.



1a: 0.2 mmol, aryl bromide: 21.5 mg (0.1 mmol), catalyst: 7.2 mg (0.01 mmol), Ag_2O : 70 mg (0.3 mmol), dioxane: 0.22 mL

In a glovebox, the catalyst, aryl bromide and Ag₂O were added to a 7 mL vial with a stir bar. 151 μ L (0.2 mmol) of a 1.32 M solution of **1a** in dioxane was added by mechanical pipette. 69 μ L of additional dioxane was added and the vial was tightly capped and stirred at 85 °C for 14 hours. The reaction was opened and filtered through a silica plug in a Pasteur pipette with three washings of 1 mL of Et₂O. The flow-through was concentrated under vacuum and 500 μ L of benzene-d₆ containing 0.1 M 1,4-dimethoxybenzene was added. The solution was analyzed by ¹H-NMR to determine yield. Percent stereoretention was calculated by subtracting the percent of the major enantiomer of **3a** from the percent of the major enantiomer of **1a**. Then that quantity was subtracted from 100 to give percent stereoretention. The stereoretention was found to be 92%. Yield was 75%. The e.r. was determined by chiral-GC using a CP chiral-DEX CB Column (30 m x 320 μ m x 0.25 μ m). Conditions: 75 °C, 10 min; 5 °C/min to 105 °C and hold. Enantiomers of **3a** eluted at 32.9 minutes and 34.0 minutes.



(S)-3-phenylbutyric acid: 331 mg (2 mmol), LAH, 95%; 88 mg (2.2 mmol), THF: 13.5 mL

The substrate was added to a round-bottom flask under N_2 with a reflux condenser containing LAH and THF. The mixture was stirred at reflux for 15 hours. Aqueous

Rochelle salt and water were added to quench the reaction. The reaction was extracted three times with DCM. The combined organic phase was dried with Na_2SO_4 and concentrated under vacuum. The residue was filtered through a silica plug with EtOAc and concentrated again to 311 mg oil. This alcohol (S)-3-phenylbutan-1-ol (**14**) was used 5 directly in the next step.

14: 310 mg (2.0 mmol), pyridine: 1 mL, toluenesulfonyl chloride: 419 mg (2.2 mmol)

14 was combined with pyridine and TsCl in a 40 mL capped vial and stirred at room 10 temperature for 5 hours until complete conversion was seen by TLC. 1 M HCl was added and the reaction was extracted three times with Et_2O . The combined organic phase was washed with 1 M HCl, H_2O , saturated NaHCO_3 , and dried with Na_2SO_4 and concentrated under vacuum. The crude was purified by silica column using 5% to 15% EtOAc in 15 hexanes. 460 mg of tosylate **15** ((S)-3-phenylbutyl 4-methylbenzenesulfonate) was obtained as a colorless oil, 74% yield from **9**.

15: 450 mg (1.45 mmol), NaBH_4 : 281 mg (7.25 mmol), DMSO: 8 mL

15 was combined with DMSO and NaBH_4 in a 20 mL vial and stirred under N_2 at 20 70°C for 14 hours. After complete consumption of **15**, the reaction was quenched with H_2O and extracted four times with n-pentane. The pentane phase was washed with water three times and dried with Na_2SO_4 . This was concentrated under light vacuum to give **16** as a colorless oil. 128 mg, 48%. $[\alpha]^{20}_D = +27.4^\circ$ ($c = 1.0, \text{CHCl}_3$)


25 **16**: 27 mg (0.2 mmol), I_2 : 2.5 mg (0.01 mmol), Br_2 : 12.4 μL (0.24 mmol), DCM: 0.5 mL

16 was combined with iodine and DCM in a 7 mL vial. Neat bromine was added dropwise in an ice bath with stirring. The reaction was stirred at room temperature open to the air for 2 hours, then quenched with 0.5 M KOH. The reaction was extracted three times 30 with DCM, then dried with Na_2SO_4 and concentrated under vacuum. NMR showed a 1:1 ratio of **16** to 4-bromo-[1-(2-butyl)]benzene. This mixture was used directly in the next step.

Crude mixture: 23 mg, Pd(PPh₃)₄: 1.7 mg (0.0015 mmol), phenylboronic acid: 24 mg (0.2 mmol), K₂CO₃: 236 mg (1.7 mmol), THF: 0.8 mL, H₂O: 0.57 mL

All reagents except water were combined in a 20 mL vial in a glovebox. In the
 5 hood, water was added and the headspace was purged with N₂ before capping and stirring at room temperature for 10 hours at 75 °C. TLC in 100% pentane shows desired product. The THF was removed under vacuum and the aqueous phase was extracted with pentane three times. The pentane extracts were dried with Na₂SO₄ and concentrated under vacuum. Product was purified by silica column using 100% pentane. 12.3 mg colorless oil obtained.
 10 ¹H-NMR showed this to be **3c** with minor impurities.

Example 16.



Compound **3c** was synthesized by the same cross-coupling procedure as described
 15 above in Example 15 for the synthesis of **3a**. The sample of **1a** was made from resolved 5 of 97:3 dr. The absolute stereochemistry of **3c** was determined by chiral HPLC comparison to **3c** and racemic **3c**. NMR spectrum was identical to that of **3c**. Racemic **3c** was prepared by cross-coupling of racemic **1a** by the same procedure as described for the synthesis of **3a**. A Chiralcel OD-H column was used, eluting with 100% n-heptane at 1.2 mL/minute and
 20 detection at 220 nm and 254 nm. (S) retention time: 9.5 min. (R) retention time: 14.6 min.

EQUIVALENTS

One of ordinary skill in the art will appreciate that starting materials, reagents,
 synthetic methods, purification methods, analytical methods, assay methods, and biological
 25 methods other than those specifically exemplified can be employed in the practice of the disclosure without resort to undue experimentation. All art-known functional equivalents, of any such materials and methods are intended to be included in this disclosure. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of

excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the disclosure. Thus, it should be understood that although the present disclosure has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts 5 herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this disclosure as defined by the appended claims.

Although the present disclosure has been described with reference to certain embodiments thereof, other embodiments are possible without departing from the present 10 disclosure. The spirit and scope of the appended claims should not be limited, therefore, to the description of the preferred embodiments contained herein. All embodiments that come within the meaning of the claims, either literally or by equivalence, are intended to be embraced therein. Furthermore, the advantages described above are not necessarily the only advantages of the disclosure, and it is not necessarily expected that all of the described 15 advantages will be achieved with every embodiment of the disclosure.


INCORPORATION BY REFERENCE

All references throughout this application, for example patent documents including issued or granted patents or equivalents; patent application publications; and non-patent 20 literature documents or other source material; are hereby incorporated by reference herein in their entireties, as though individually incorporated by reference, to the extent each reference is at least partially not inconsistent with the disclosure in this application (for example, a reference that is partially inconsistent is incorporated by reference except for the partially inconsistent portion of the reference).

CLAIMS

We claim:

1. A method of forming a product represented by R^1R^2CH-Ar , comprising: combining a secondary boronic acid represented by $R^1R^2CH-B(OH)_2$; an aryl halide represented by $Ar-X$; a Pd catalyst; a ligand; and Ag_2O :



wherein, independently for each occurrence,

R^1 and R^2 are selected from the group consisting of substituted C_1-C_6 alkyl and unsubstituted C_1-C_6 alkyl; or R^1 and R^2 , taken together with the carbon to which they are joined, form a substituted or unsubstituted C_3-C_8 cycloalkyl;

Ar represents a substituted or unsubstituted monocyclic or polycyclic aryl;

X represents halogen;

Pd catalyst represents Pd(0) or Pd(II);


ligand is $P(o-R\text{-phenyl})_3$; and

R represents C_1-C_4 alkyl;

thereby forming a product represented by R^1R^2CH-Ar .

2. The method of claim 1, wherein Pd catalyst represents Pd(0).
3. The method of claim 1, wherein Pd catalyst represents Pd(II).
4. The method of claim 1, wherein ligand is $P(o\text{-tol})_3$.
5. The method of any one of claims 1-4, wherein the secondary boronic acid is achiral.
6. The method of any one of claims 1-4, wherein the secondary boronic acid is chiral.
7. The method of claim 6, wherein the secondary boronic acid is a racemic mixture.
8. The method of claim 6, wherein the secondary boronic acid is not a racemic mixture.

9. The method of claim 8, wherein the secondary boronic acid has an enantiomeric excess of at least 80 percent.
10. The method of claim 8, wherein the secondary boronic acid has an enantiomeric excess of at least 90 percent.
11. The method of claim 8, wherein the secondary boronic acid has an enantiomeric excess of at least 95 percent.
12. The method of claim 6, wherein the product represented by R^1R^2CH-Ar is not a racemic mixture.
13. The method of claim 8, wherein the product represented by R^1R^2CH-Ar has an enantiomeric excess of at least 80 percent.
14. The method of claim 8, wherein the product represented by R^1R^2CH-Ar has an enantiomeric excess of at least 90 percent.
15. The method of claim 8, wherein the product represented by R^1R^2CH-Ar has an enantiomeric excess of at least 95 percent.
16. The method of any one of claims 1-15, wherein R^1 and R^2 are selected from the group consisting of substituted C_1-C_6 alkyl and unsubstituted C_1-C_6 alkyl.
17. The method of any one of claims 1-4 and 6-15, wherein R^1 and R^2 , taken together with the carbon to which they are joined, form a substituted or unsubstituted C_3-C_8 cycloalkyl.
18. The method of any one of claims 1-17, wherein Ar represents a substituted or unsubstituted phenyl.
19. The method of any one of claims 1-17, wherein Ar represents a substituted or unsubstituted polycyclic aryl.
20. The method of any one of claims 1-19, wherein X is Br.
21. The method of any one of claims 1-19, wherein X is I.
22. A method of forming an air-stable chiral secondary boronic acid, wherein the air-stable chiral secondary boronic acid is not a racemic mixture, comprising:
 - combining a chiral secondary boronic acid represented by formula (I)



(I)

wherein, independently for each occurrence, R¹ and R² are selected from the group consisting of substituted C₁-C₆ alkyl and unsubstituted C₁-C₆ alkyl; a chiral iminodiacetic acid, wherein the chiral iminodiacetic acid is not a racemic mixture; a weak acid catalyst; and a polar aprotic solvent, thereby forming a mixture of chiral boronates; resolving the mixture of chiral boronates into individual diastereomers; and hydrolyzing an individual diastereomer, thereby forming an air-stable chiral secondary boronic acid, wherein the air-stable chiral secondary boronic acid is not a racemic mixture.

23. The method of claim 22, wherein the resolving is by crystallization.
24. The method of claim 22, wherein the resolving is by chromatography.
25. The method of any one of claims 22-24, wherein the hydrolyzing is with aqueous hydroxide.
26. The method of any one of claims 22-24, wherein the hydrolyzing is with aqueous NaOH.
27. The method of any one of claims 22-26, wherein the chiral iminodiacetic acid has an enantiomeric excess of at least 80 percent.
28. The method of any one of claims 22-26, wherein the chiral iminodiacetic acid has an enantiomeric excess of at least 90 percent.
29. The method of any one of claims 22-26, wherein the chiral iminodiacetic acid has an enantiomeric excess of at least 95 percent.
30. The method of any one of claims 22-29, wherein the chiral iminodiacetic acid is benzylcyclopentyl iminodiacetic acid (BIDA).
31. The method of any one of claim 22-30, wherein the weak acid catalyst is pyridinium *p*-toluenesulfonate (PPTS).

32. The method of any one of claims 22-31, wherein the polar aprotic solvent is CH₃CN.

33. The method of any one of claims 22-32, wherein the chiral secondary boronic acid represented by formula (I) is a racemic mixture.

34. The method of any one of claims 22-32, wherein the chiral secondary boronic acid represented by formula (I) is not a racemic mixture.


35. The method of any one of claims 22-34, wherein the air-stable chiral secondary boronic acid has an enantiomeric excess of at least 80 percent.

36. The method of any one of claims 22-34, wherein the air-stable chiral secondary boronic acid has an enantiomeric excess of at least 90 percent.

37. The method of any one of claims 22-34, wherein the air-stable chiral secondary boronic acid has an enantiomeric excess of at least 95 percent.


38. A method of forming an air-stable trihydroxyborate salt of a primary or secondary boronic acid, comprising:

(i) combining a primary or secondary boronate represented by formula (II):



(II)

a first polar aprotic solvent, and aqueous hydroxide, thereby forming a primary or secondary boronic acid represented by formula (I):



(I);

wherein, independently for each occurrence,

R¹ is selected from the group consisting of substituted C₁-C₆ alkyl and unsubstituted C₁-C₆ alkyl;

R^2 is selected from the group consisting of H, substituted C_1 - C_6 alkyl and unsubstituted C_1 - C_6 alkyl; and

R^a and R^b are selected from the group consisting of optionally substituted alkyl, aryl, and acyl; or R^a and R^b taken together with the $-O-B(CHR^1R^2)-O-$ moiety to which they are attached form an optionally substituted heterocyclic ring consisting of 5-10 heavy atoms in the backbone of said heterocyclic ring, wherein 3-5 heteroatoms selected independently from the group consisting of B, O, and N are present in said heterocyclic ring; and


(ii) combining the primary or secondary boronic acid represented by formula (I), an ether, and concentrated hydroxide, thereby forming an air-stable trihydroxyborate salt of a primary or secondary boronic acid.

39. The method of claim 38, further comprising combining the air-stable trihydroxyborate salt of a primary or secondary boronic acid, a Lewis acid, and a second polar aprotic solvent, thereby re-forming the primary or secondary boronic acid represented by formula (I).

40. The method of claim 39, wherein the Lewis acid is BF_3OEt_2 .

41. The method of claim 38 or 39, wherein the second polar aprotic solvent is dioxane.

42. The method of any one of claims 38-41, wherein the primary or secondary boronate represented by formula (II) is represented by formula (III):



(III)

wherein, independently for each occurrence,

R^1 is selected from the group consisting of substituted C_1 - C_6 alkyl, and unsubstituted C_1 - C_6 alkyl;

R^2 is selected from the group consisting of H, substituted C_1 - C_6 alkyl, and unsubstituted C_1 - C_6 alkyl;

B represents boron having sp^3 hybridization; and

R^{20} , R^{21} , R^{22} , R^{23} , and R^{24} independently are selected from the group consisting of a hydrogen group and an organic group.

43. The method of claim 42, wherein R^{21} , R^{22} , R^{23} , and R^{24} each represent a hydrogen group.

44. The method of any one of claims 38-43, wherein the primary or secondary boronate represented by formula (II) is achiral.


45. The method of any one of claims 38-44, wherein the primary or secondary boronic acid represented by formula (I) is a primary boronic acid.

46. The method of any one of claims 38-44, wherein the primary or secondary boronic acid represented by formula (I) is a secondary boronic acid.

47. The method of any one of claims 38-44, wherein the air-stable salt of the primary or secondary boronic acid is achiral.

48. The method of any one of claims 38-43, wherein the primary or secondary boronate represented by formula (II) is chiral.

49. The method of claim 48, wherein the primary or secondary boronate represented by formula (II) is represented by formula (IV):



(IV).

50. The method of claim 48 or 49, wherein the primary or secondary boronic acid represented by formula (I) is a primary boronic acid.

51. The method of claim 48 or 49, wherein the primary or secondary boronic acid represented by formula (I) is a secondary boronic acid.

52. The method of claim 51, wherein the secondary boronic acid is achiral.

53. The method of claim 51, wherein the secondary boronic acid is chiral.


54. The method of claim 53, wherein the chiral secondary boronic acid represented by formula (I) is a racemic mixture.
55. The method of claim 53, wherein the chiral secondary boronic acid represented by formula (I) is not a racemic mixture.
56. The method of any one of claims 48-55, wherein the chiral primary or secondary boronate represented by formula (II) is a racemic mixture.
57. The method of any one of claims 48-55, wherein the chiral primary or secondary boronate represented by formula (II) is not a racemic mixture.
58. The method of claim 57, wherein the chiral primary or secondary boronate represented by formula (II) has an enantiomeric excess of at least 80 percent.
59. The method of claim 57, wherein the chiral primary or secondary boronate represented by formula (II) has an enantiomeric excess of at least 90 percent.
60. The method of claim 57, wherein the chiral primary or secondary boronate represented by formula (II) has an enantiomeric excess of at least 95 percent.
61. The method of claim 53, wherein the air-stable salt of the primary or secondary boronic acid is a chiral air-stable salt of the secondary boronic acid.
62. The method of claim 61, wherein the chiral air-stable salt of the secondary boronic acid is a racemic mixture.
63. The method of claim 61, wherein the chiral air-stable salt of the secondary boronic acid is not a racemic mixture.
64. The method of claim 63, wherein the chiral air-stable salt of the secondary boronic acid has an enantiomeric excess of at least 80 percent.
65. The method of claim 63, wherein the chiral air-stable salt of the secondary boronic acid has an enantiomeric excess of at least 90 percent.
66. The method of claim 63, wherein the chiral air-stable salt of the secondary boronic acid has an enantiomeric excess of at least 95 percent.
67. The method of any one of claims 38-66, wherein the first polar aprotic solvent is tetrahydrofuran (THF).

68. The method of any one of claims 38-67, wherein the aqueous hydroxide is aqueous NaOH.

69. The method of any one of claims 38-68, wherein the ether is methyl *tert*-butyl ether (MTBE).

70. The method of any one of claims 38-69, wherein the concentrated hydroxide is concentrated NaOH.

71. A method of forming a boronic acid, comprising the steps represented by:



wherein

R^a represents an organic group; and

MIDA represents N-methyliminodiacetic acid.

72. The method of claim 71, wherein the weak acid catalyst is pyridinium *p*-toluenesulfonate (PPTS).

73. The method of claim 71 or 72, wherein the first polar aprotic solvent is CH₃CN.

74. The method of any one of claims 71-73, wherein the base is NaOH.

75. The method of any one of claims 71-74, wherein the second polar aprotic solvent is tetrahydrofuran (THF).

76. The method of any one of claims 71-75, wherein the organic group is a chiral

organic group; and the boronic acid $\text{R}^a\text{-B(OH)}_2$ is a chiral boronic acid.

77. The method of claim 76, wherein the chiral organic group is a racemic mixture; and the chiral boronic acid is a racemic mixture.

78. The method of claim 76, wherein the chiral organic group is not a racemic mixture; and the chiral boronic acid is not a racemic mixture.

79. The method of claim 78, wherein the chiral organic group has an enantiomeric excess of at least 80 percent.

80. The method of claim 78, wherein the chiral organic group has an enantiomeric excess of at least 90 percent.


81. The method of claim 78, wherein the chiral organic group has an enantiomeric excess of at least 95 percent.

82. The method of claim 78, wherein the chiral boronic acid has an enantiomeric excess of at least 80 percent.

83. The method of claim 78, wherein the chiral boronic acid has an enantiomeric excess of at least 90 percent.


84. The method of claim 78, wherein the chiral boronic acid has an enantiomeric excess of at least 95 percent.

Figure 1




Scheme 1

Figure 2



Scheme 2

Figure 3



Scheme 3

Figure 4

